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Introduction For Annual Aeport
You might ask, “Why focus on a
tumor site in our annual cancer
program report that accounts for less
than one in twenty patients diagnosed
with malignancy?” We chose head
and neck cancers for three reasons.
First, many are preventable and
unfortunately a number of our young
people are taking up the behaviors
Morcio J.5. Aichords, MD
that lead to this type of malignancy.
Choirperson o Concer
Second, head and neck cancers are
Commtee
incredibly complex. I know of no
other area where the site can move one centimeter or the
tumor size change one centimeter and have treatment
altered as rapidly as in the head and neck region. Lastly,
many tumors involve complex integration of all treatment
modalities in numerous ways (again varying by site and
size), aimed at balancing the potential cure rate while
preserving function when possible. These factors all
contribute to the need for every person in the medical area
to be aware of these tumors. Awareness through public
and preventative measures, may result in a reduced
incidence of these tumors, with an improved cure rate and
functionality when they do occur.
.

As chair of the Cancer Committee, I want to report on our
activities for the year. We were again goal driven for the
year.

Cancer Committee Goals For I 996 1997
.

Outreach: enhance patient and community education
about cancer prevention, early detection, and our cancer
services.

.

Care Coordination: track outcomes of cancer programs
and, strengthen integration between our program and
physician’s offices to facilitate integrated delivery of care.

.

Care Evaluation: perform patient care studies.

.

Patient/Family/Staff Support: integrate psychosocial
programs more effectively and develop formalized
mechanisms for support of cancer services staff.

.

Research: increase participation in clinical trials.

We continued to focus on care improvement for breast
cancer patients with an improved method for collection of
patient data via a task force, chartered through the Quality

Council. Special educational events included a symposium
held on head and neck cancer. Prostate cancer was also
highlighted with a second educational symposium in the
fall, creatively entitled, Surveillance, Surgery, Seeds and
Sexuality: What’s New in Prostate Cancer? both with
nationally known participants and coordinated by the
surgical subcommittee.
“

“,

Q uality management efforts included an outcome study on
patients treated for early laryngeal cancer, a study on
patients receiving bladder preservation, and the creation of
an “Outcome Variance Tracking Tool” for ABMT patients.
In addition to our internal studies, we participated in the
American College of Surgeon studies1on soft tissue
sarcoma, thyroid cancer, and prostate cancer treated by
radical prostatectomy. As an additional quality effort, the
Cancer Committee decided to appoint an advising/educa
tional physician to the Cancer Registry. Dr. Jonathan
Treisman volunteered for the role.
Community outreach activities included a Cancer Survivor
Day Celebration”, and of course, the Vince Lombardi Golf
Classic and Award of Excellence Dinner Ball. We do continue to highly appreciate all the Lombardi volunteers.
“

New program areas include a new operating stereotactic
microscope for neurosurgery, photopheresis for cutaneous
T-cell Lymphoma, a research newsletter called the Pioneer
for medical staff, and a computer based education and
support system for breast cancer patients. In radiation
oncology a high dose rate brachytherapy program was
started and the permanent prostate seed implant program
was implemented. A pain management protocol was
developed cooperatively with the VNA for management of
hospice and other outpatients. Also, a Neuro-Oncology
Task Force was started for program development. In
addition, a gift was donated to provide videos for patients
making a decision on whether to have a PSA screening
done.
Once again it has been a busy, productive and challenging
year.
Marcrij& Richards, MD
Cancer Committee Chair

Head and Neck Cancer
Once a diagnosis of head and neck cancer has been made,
treatment planning is begun. This is ideally done in a team
approach involving the otolaryngologist-head and neck
surgeon, radiation oncologist, and medical oncologist.
Treatment options for squamous cell carcinoma of the head
and neck vary depending on tumor stage and location.
Frequently, early stage lesions may be treated with surgery
or radiation therapy with equal effectiveness. Under these
circumstances, arriving at the best treatment plan the
patient’s overall health, occupation, reliability, proximity to
treatment facilities, and the expected morbidity with each
treatment modality, need to be considered. More advanced
tumors traditionally have been addressed with combined
modality treatment utilizing sujgery with post-operative
radiation therapy. Historically, chemotherapy has been
reserved for palliative care of patients with end stage
disease who have exhausted surgical and radiotherapeutic
options. Today, however, for certain advanced tumors
chemotherapy in conjunction with radiotherapy is accepted
as first course therapy. The major advantage, in these
patients, previously destined to total laryngectomy, is a
65 % chance of laryngeal preservation.

Cancer of the head and neck repre
sents less than 5 % of newly diagnosed
cancers and is seen almost exclusively
in patients with well recognized risk
factors. Tobacco (smoking and
smokeless) and alcohol use are the
most significant and commonly identi
fied agents linked to the development
of squamous cell carcinoma.
Michael A. Nordstrom, M.D.
Smoking is present in 95 % of
OoIoryngotogy
Head & Neck Surgery
patients. Alcohol use or abuse,
especially in association with cigarette
smoking, contributes to an increased
risk of cancer development. In addition to these well
recognized factors, Epstein-Barr virus (E.B.V.), human
papilloma virus (H.P.V.) and gastroesophageal reftux
contribute to the evolution of squamous cell carcinoma. It
is a rare occurrence for a patient to present with head and
neck cancer in the absence of any risk factors.
The majority of cancers of the head and neck are squamous
cell carcinomas arising from the squamous epithelium
lining the upper aerodigestive tract. Although young
people may be affected, most patients are men in their
sixties, seventies and eighties. The oral cavity and larynx
are the most commonly affected sites followed by the
oropharynx, hypopharynx and nasopharnyx.
Nonsquamous cancers, including salivary gland, thyroid,
neuroendocrine, sarcoma, and lymphoma, represent most
of the remaining 5%. The factors associated with
squamous cell carcinoma are not associated with these
other types of tumors.

In patients with squamous cell carcinoma, particularly
those who continue to engage in risky behavior, the chance
of developing a second primary cancer may be as high as
1 5 % Ex-smokers are still considered to be at risk long
after they quit. The risk of cancer in ex-smokers takes
approximately 15 years to even approach that of a nonsmoker. Lifelong cancer surveillance examinations in
patients treated for head and neck cancer are therefore
recommended.
.

A mukispecialty team approach is very important in
addressing the needs of head and neck cancer patients. The
impact of disease, as well as treatment, on quality of life
can be tremendous considering the complex anatomy and
function of the sites affected by these tumors. The possibility
of the loss of speech, taste, swallow function, disfigurement, as well as, all the other fears universal to patients
diagnosed with cancer can be terrifying. Team involvement in diagnosis and treatment is equally critical in
rehabilitation and palliative care.

Symptom development and subsequent diagnosis vary
significantly depending on tumor location. Early symptoms
may be vague and nonspecific, easily attributable to more
common, benign, and self-limited conditions. These may
include very mild complaints of hoarseness, throat
discomfort, dysphagia, or ear pain, which in retrospect may
predate diagnosis by as much as a year. Small tumors of
the larynx frequently result in significant hoarseness
prompting early evaluation and recognition at a stage
where cure rates may be high and associated morbidity of
treatment relatively low. Conversely, some tumors (e.g.
tongue base or hypopharnyx) may reach advanced stages
before prominent symptoms occur. Significant weight loss,
odynophagia, dysarthria or the development of a neck
mass, may represent more advanced disease. The resulting
delay in diagnosis not only negatively impacts the
prognosis, but may result in the need for far more extensive
therapy and devastating impact on the quality of life. Early
detection and evaluation of persistent symptoms with a
thorough head and neck examination will greatly impact
the majority of these patients.

In the future, investigational protocols will help define the
role of nonsurgical intervention that effectively treats the
tumor while preserving the normal complex function of the
upper aerodigestive tract. A phase II clinical trial beginning
soon will introduce gene therapy into the head and neck
cancer arena. Deficiencies or abnormalities of the tumor
suppressor gene p53 occur frequently in primary and recurrent squamous cell carcinoma. In phase I animal studies,
an attenuated Group C adenovirus which replicates and
subsequently lyses cells deficient in p53 while remaining
2

inactive in normal cells has been shown to inhibit tumor
cell growth and increase survival time by 40%.
Advancements in gene therapy and immunotherapy in
years to come will hopefully allow us to fight cancer at the
molecular level, targeting tumor cells and preserving
normal tissue, while improving survival and quality of life.
Until then, prevention and early detection continue to be
practiced.

SMOKING HISTORY
Head and Neck Cancers
(Excluding Sinus, Thyroid, Salivary Glands & Lymphomas)
Never Smoked
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Mithae/R. Nordstrom MD.
Otolaryngology
Head & Neck Surgery
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According to a Professional Education Publication from the American
Cancer Societ non-drinking smokers have 2 to 4 times the risk of
developing cancer compared with those who abstain from both
alcohol and tobacco. The risk of smokers who are heavy drinkers is 6 to
1 5 times that of abstainers. At St. Luke’s Medical Center the ratio of
patients diagnosed with head and neck cancer in 1 996 who were
current smokers or had a history of smoking to those patients who never
smoked is more than 4 to 1,

Head and Neck Cancer Screening
St. Luke’s Medical Center recommends that individuals with the following significant risk factors for the
head and neck cancei consider taking advantage of the free Head and Neck Cancer
Screening Program available as part of our Head and Neck Cancer Services.

development of

1 Heavy smoking (greater than 1 pack per day) currently or within previous S years, especially if
concurrent with alcohol use.
.

2. Regular smokeless tobacco use.
3. History of head and neck irradiation.
4. Personal history of head and neck cancer.
5. Persistent hoarseness (greater than 1 month) with smoking histor)c
6. Nonhealing sore on head or neck.
7. Lump or nodule on head or neck.
Periodic head and neck screenings are held in the Vince Lombardi cancer Clinic. If you have questions
concerning the screening program or are interested in the next available date, please call the Vince Lombardi
Cancer Hotline at 649-7200 or Susan Nuccio, RN, Head and Neck Cancer Coordinator at 649-7823.
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According to Cancer Facts & Figures-i 996 an estimated 29,490 new oral and pharyngeal cancer cases will be diagnosed in i 996. The number of
new cases in men each year is more than iwice as high as in women. This coincides with the ratio of men to women diagnosed with all head and
neck cancers, at St Luke’s Medical Center in i 996, with the exception of nasopharynx and thyroid cancer.
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1996 AJCC STAGE
ALL HEAD AND NECK SITES
(Excluding Thyroid, Sinus,
Salivary Glands & Larynx)
Stage III
14% (4)

Stage iv:
43% (12)

—

Stage iv
7% (2)

Stage
4% (1)

According to Head and Neck Cancer, a journal by The American
Cancer Society clinical size and symptomatology are directly related,
therefore, most oral cancers are detected only after they become
symptomatic, At St, Luke’s Medical Center, 64% of head and neck
cancers are detected at stage 2, 3 or 4 compared to 32% at stage 1

1996 LARYNX AJCC STAGE
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Radiographic Imaging oF the Head and Neck
The imaging of the skull base and
neck continues to be a challenge to
the diagnostic imager. This is due to
the small size of the structures being
evaluated, the complexity of the
anatomy, and patient motion.
However, recent advances in imaging
technology now allow for higher
resolution images with shorter scan
times. This results in better image
quality and increased accuracy.

MRI are, superior soft tissue contrast for primary tumor
staging, not requiring iodinated contrast, and better multiplanar capability. At this time, if there are no contraindica
tions, the spiral CT scan with iodinated contrast is the first
choice for staging. Some areas, such as the skull base, may
require a combination of the two studies to evaluate both
the bone and the soft tissues.
New advances in staging and surgical planning include
three dimensional imaging and ultrasound guided fine
needle aspiration of lymph nodes. Three dimensional CT
images are actually a series of thin two dimensional images
that are summed by a computer. These are most useful
when evaluating bony structures and they can provide a
useful model for surgical planning. The surgery can be
simulated to a degree on the computer where sections of
bone can be removed and accurate measurements for
prosthetics can be obtained.

Peter A. Bessee, MD
Aodiology Diognosuc &
Medicol Imoging

The role of the diagnostic imager in head and neck cancer
is broken down into pre-therapy and post-therapy roles.
Pre-therapy roles include staging, unknown primary tumor
search, and radiation therapy port planning. Post-therapy
roles include treatment assessment and evaluation of tumor
recurrence.

Fine needle aspiration of borderline lymph nodes is
currently being assessed as another aid to staging.
Ipsilateral and contralateral lymph nodes can be aspirated
with ultrasound guidance and evaluated for the presence of
micrometastases. This may
be helpful during surgical
planning for patients at
risk for increased
morbidity due to extensive
neck dissection.

The first pre-therapy role of imaging is accurate staging.
Accurate staging occurs when the clinical stage, that is, the
clinicians visual and tactile observations are combined with
the radiological stage obtained either with CT or MRI.
Prior studies have shown that
MRI or CT staging will
upgrade the clinical stage in
25% of cases. The clinician
will be able to provide a
better estimate of mucosal
spread of tumor. Imaging
will provide a better assessment of the deep tissue extent
and enlarged or border line
lymph nodes that may not be
palpable. Also, imaging will
provide staging information
in relative blind spots for the
clinician, such as the
nasopharynx.
The choice of CT or MRI for
staging can be a difficult one.
The advantages of CT are
faster acquisition times,
decreased cost (compared to
MRI), better sensitivity for
bone destruction, and better
sensitivity for metastatic
adenopathy. Also, it can be
used for most patients who
are claustrophobic or who
are not MRI candidates due
to pacemakers or aneurysm
clips. The advantages of

Another role of imaging in
the neck is the unknown
primary tumor search. An
example of this would be
the detection of squamous
cell carcinoma in enlarged
lymph nodes, however, no
obvious primary tumor site
is seen on any mucosal
surface in the upper aerodi
gestive tract. Frequent
sites of an unknown
primary are in areas that
are difficult to directly
visualize including the
nasopharynx, inferior
aspect of the pyriform
sinus, and the faucial and
lingual tonsillar crypts.

A single axial slice rom a three dimensional MA scan showing a
high signal moss (choIeserol gronulomo) involving he right
perous bone.
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A third pre-therapy role of
imaging is radiation
therapy port planning. In
this situation MRI with
coronal and sagittal images

can provide excellent assistance as they can be translated
onto AP and lateral simulation films and provide an
accurate assessment of tumor extent.

patient undergo a baseline scan at the 12th post-operative
week and then undergo repeat exams every 4 to 6 months
for the next 2 to 3 years. Most recurrences develop in the
first 2 years.

The first post-therapy role of imaging is to evaluate the
response to treatment (radiation and chemotherapy). This
is usually easily done by assessing change in the size of the
tumor and lymph nodes. Imaging is most helpful in those
areas that are inaccessible to site or touch.

New technologies are being evaluated to detect recurrence.
These include magnetization transfer ratios, and MR
spectroscopy. These are MRI methods that exploit
differences in the chemical make up of tumors and normal
tissue in an effort to differentiate the two at the macromol
ecular level. These techniques are promising but are
presently experimental.

The second post-therapy role is diagnosis of tumor
recurrence. This is one of the most important and most
difficult tasks for head and neck imaging. This is due to
the local tissue insult caused by surgery and radiation. The
majority of hemorrhagic and edematous changes will
resolve in the 4th to 6th post-operative week. However, in
some patients receiving both surgery and radiation, these
changes may last for 12 to 1 8 months and this hinders the
evaluation of recurrence. It is recommended that the

The accurate assessment of head and neck cancer requires a
combination of clinical information and meticulous appli
cation of available imaging techniques. This will remain a
challenge for the diagnostic imager and requires ongoing
research in pre-therapy and post-therapy imaging.
Peter R. Bessette, MD
Radiology Drzgnothc & Medical Imaging

Three dimensional image o he mandible showing a IyEic lesion o he riqh angle.
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The Role oF Pathology in the Diagnosis and Management ol
Squamous Cell Carcinoma oF the Head and Neck
Histopathologic evaluation of biopsy
and resection specimens is a critical
component of both initial evaluation
and follow-up of patients with head
and neck carcinoma. The clinical sus
picion of malignancy requires biopsy
confirmation. In addition, important
prognostic information is obtained
from biopsy and resection specimens.
This information is critical to guiding
appropriate clinical management of
head and neck cancer patients.

head and neck cancers, although false negative results may
occur due to post-radiation fibrosis, small tumors or
necrosis. False positive test results are rare but may occur
due to post-radiation atypia which may show atypical or
even bizarre cells mimicking malignancy.
In patients presenting with symptoms referable to the upper
aerodigestive tract, such as hoarseness, diagnostic material
is usually obtained via direct or endoscopic biopsy of an
identifiable lesion. In small biopsies, the most critical piece
of information is the histopathologic diagnosis. While a
wide variety of malignancies may involve the upper aerodi
gestive tract, in excess of 95 % of head and neck cancers are
of squamous cell type. A histologic grade is usually
assigned to such lesions. However, superficial biopsies may
not accurately reflect the degree of differentiation in larger
lesions. In addition, there are conflicting data on the
prognostic significance of histologic grading of squamous
cell carcinomas of the head and neck. In some studies, the
degree of differentiation was second only to nodal stage as
a prognostic factor for tumor cure. Other studies were
unable to demonstrate any affect of histologic grade on
local recurrence, but noted that poorly differentiated
tumors were more likely to give rise to lymph node
metastases. On the other hand, well differentiated primary
tumors are less likely to be cured by radiotherapy than are
moderately or poorly differentiated lesions.

GQry F. Neitzel, MD
toboroory Medicine

In patients presenting with palpable masses of the head and
neck, a fine needle aspiration (FNA) biopsy should be
considered in the initial evaluation. Masses in the neck
may be due to a wide variety of disorders involving a
variety of structures including salivary glands, lymph nodes,
thyroid, skin and soft tissue. In adults, neck masses follow
the rule of 80; i.e., 80% of non-thyroid neck masses are
neoplastic, 80% of these neoplasms are malignant, 80% of
malignant masses represent metastatic disease, and 80% of
primary tumors are located above the clavicle. Occult head
and neck carcinoma may present as an enlarged cervical
lymph node. In some cases, the primary tumor is never
detected. Squamous cell carcinomas account for at least
55% of head and neck cancers. Not surprisingly, the single
most common malignant diagnosis in FNA biopsy of head
and neck masses is squamous cell carcinoma.

Additional important prognostic information can be
garnered from resected tumor specimens. Local extent of
the primary tumor is an important prognostic factor. In
general, the T category in the TNM staging scheme
correlates quite well with the prognosis. In head and neck
cancers, it is important to note that T category tumors
cannot be grouped together as the staging criteria vary for
different sites within the upper aerodigestive tract. In some
sites, the T category is based mainly on the dimensions of
the tumor while in other sites it is based largely on local
extension to adjacent structures. As a consequence, tumors
in the same T category may have very different prognoses.
Tumor volume may correlate better with prognosis than T
status. In other studies, the depth of tumor infiltration or
tumor thickness proved to be prognostically significant,
more so that the surface extent of the lesion (T status). In a
series of early stage floor of mouth and tongue cancers, the
depth of invasion was directly related to the risk of
subsequent regional nodal metastases on ultimate survival.
A similar finding was noted in the study of carcinomas
involving the soft palate.

Fine needle aspiration biopsy offers some distinct
advantages over open biopsy of palpable neck masses. In
general, the tumor and tissue planes about the tumor
should not be violated until the time of definitive therapy.
Open or incisional biopsies can contaminate the operative
field with tumor, increasing the likelihood of local
recurrence and metastases of head and neck malignancies.
When metastatic head and neck squamous cell carcinoma
recurs after tissue biopsy of a cervical lymph node, it
invariable does so at the site of that biopsy. Open biopsy
may also induce scarring which may interfere with
subsequent surgery, and cause cosmetic problems. None of
these complications occur following FNA biopsy.
FNA biopsy is safe, cost effective and reliable. In experi
enced hands, an overall sensitivity of approximately 95%
and specificity of approximately 98 % can be achieved in
lesions of the head and neck. Unsatisfactory specimens
range from 0 to approximately 20%, depending in large
part on the experience of the operator. FNA biopsy is
particularly useful in diagnosing recurrent or metastatic

8

carcinomas. Histologic evaluation of the resection margins
during the operation helps to ensure complete resection of
the tumor. Open communication between the pathologist
and surgeon before, during, and after the operation is
critical to this evaluation. A visit to the operating room by
the attending pathologist for orientation of the specimen
and discussion of pertinent margins is often very helpful.
Complete surgical resection of a malignancy may, in some
cases, prevent the need for additional radiotherapy or
chemotherapy.

The pattern of tumor invasion may also offer prognostic
information. Tumors inrading as large cohesive aggregates
may have a better prognosis than those invading as thin
irregular cords or individual cells. The presence of
perineural tumor infiltration has been associated with a
statistically significant increase in local recurrence and
decrease in survival. Likewise, the presence of angiolym
phatic space involvement results in a statistically significant
increase in regional node metastases.
The presence of regional lymph node metastases is one of
the most important prognostic indicators in squamous cell
carcinoma of the head and neck. The presence of nodal
metastases reduces survival rates by approximately half in
both oral and supraglottic carcinomas. In general, the
presence of one involved lymph node 3 cm. or less in
diameter has only a small affect on survival and regional
tumor control, whereas larger metastatic deposits have a
pronounced affect on both these outcomes. Bilateral or
contralateral nodal involvement is thought to indicate a
nonfavorable prognosis, but this has not been confirmed in
statistical analyses.

A variety of ancillary studies have been explored in
research projects related to squamous cell carcinoma of the
head and neck. DNA ploidy studieshave provided
conflicting data. However, most series suggest that diploid
tumors have a better prognosis than aneuploid tumors.
However, other studies have suggested that aneuploid
tumors are more responsive to radiotherapy and
chemotherapy. A wide variety of tumor markers and
serum markers have been studied. While a few show some
promise, all have disadvantages including limited sensitivity
and a low degree of specificity. Genetic abnormalities, such
as point mutations, are common in squamous cell carcino
mas of the head and neck, particularly in the regions of
lp22 and 1 lpl3. These point mutations occur in
proto-oncogenes and tumor suppressor genes. While these
studies provide exciting and interesting information about
the development of malignancies, as yet they have not been
sufficiently studied to be of value in clinical practice.

The presence of extranodal infiltration in metastatic tumor
deposits is a significant finding. Spread of the tumor
beyond the capsule of the involved lymph node may be one
of the most important predictors of local recurrence in the
neck and may also predict a remarkable increase in distant
metastases. The number of involved lymph nodes,
histologic grade, and fixation of adjacent nodes are also
significant factors for local recurrence.

Gary F. Neitze/ MD
Laboratory Medicrze

Intraoperative frozen section guidance is a critical
component of the surgical management of head and neck

HISTOLOGY DISTRIBUTION FOR ALL
HEAD AND NECK CANCERS
(Excluding Thyroid) IN 1996
Number
of Cases
Histology Distribution

26
Squamous Cell Carcinoma, Malignant
9
Squamous Cell Carcinoma, Keratinizing
3
Malignant Lymphoma Diffuse Large Cell
2
Adenoid Cystic Carcinoma
1
Squamous Cell Carcinoma, In Situ
Squamous Cell Carcinoma, Nonkeratinizing 1
1
Basosquamous Carcinoma
1
Clear Cell Adenocarcinoma
1
Mucoepidermoid Carcinoma
1
Kaposi’s Sarcoma
46

TOTAL
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Surgical Treatment oF Laryngeal Cancer
Surgery is a therapeutic option for
nearly all patients diagnosed with
cancer of the head and neck, includ
ing the larynx. The first laryngectomy
was performed by Bilroth in 1873.
Except for patients deemed unre
sectable or poor surgical candidates,
the mainstream of therapy is surgical
extirpation of tumors with or without
Michael A. Nordstrom, M.D.
radiation therapy. Refinements in
Otoloryngology
Head & Neck Surgery
technique, as well as, advancements in
reconstructive options have allowed for more aggressive
surgical treatment of larger tumors and a greater ability to
restore function.
.

.

Successful endoscopic excision is not possible with exten
sion of glottic tumors to the supra- or subglottis or in the
presence of vocal cord fixation. In these advanced tumors
a more extensive open approach is necessary. Surgical
treatment for advanced laryngeal cancer has undergone
change over the years. Unfortunately, most patients with
extensive laryngeal tumors still require a total laryngectomy.
In a select few patients preservation of some laryngeal
function may be accomplished with a surgical alternative to
total laryngectomy without adversely affecting survival.
Although there has unfortunately been no significant
improvement in overall disease-free survival, there has been
a favorable impact on quality of life.

.

Traditionally, an open cervical approach (supraglottic
laryngectomy) has been used for all stages of supraglottic
cancer. This is especially true of advanced tumors. In
select Ti and T2 supraglottic cancers, an endoscopic
approach with curative intent may be undertaken.
Recognition by the surgeon of the technical limitations of
this modality, as well as, an understanding of tumor
behavior in these locations is essential. Patients undergoing
supraglottic laryngectomy require a temporary tracheostomy
for preservation and protection of the airway.
Decannulation and adequate deglutition are achieved in
approximately 90-95 % of patients. Postoperative
aspiration is expected, due to partial loss of airway
protection normally provided by the supraglottic larynx,
and therefore patients with poor pulmonary reserve are
poor supraglottic laryngectomy candidates.

With advances in radiation therapy, as well as, the
favorable results achieved in select patients utilizing
chemoradiotherapy, the role of surgical therapy is being
refined. Nonetheless, it remains an option for most
patients diagnosed with cancer of the larynx, as well as,
other sites of the head and neck.

Primary Surgical Therapy oF Loryngea Cancer
The larynx (supraglottic, glottic and subglottic) represents
one of the most common sites for the development of
squamous cell carcinoma of the head and neck. Most
occur on the glottic or supraglottic larynx. True subglottic
cancers are uncommon. Symptoms commonly develop
early, resulting in diagnosis before tumors reach advanced
stages. Conservation laryngeal surgery may be performed
on many of these tumors with curative intent while preserv
ing laryngeal functions of voice, adequate airway, and safe
deglutition. Transoral endoscopic or open cervical
approaches may be utilized for tumor resection. Individual
tumor characteristics, among other factors, must be
considered when deciding on the appropriate approach.

In addition to management of the primary tumor, the
supraglottic larynx is rich in lymphatics and cervical
metastatic disease is common, even in very early lesions.
Management of the neck in these cases may influence the
approach to the primary lesion.

Cancers arising on the true vocal cords are frequently
amenable to transoral endoscopic approaches. This is
usually accomplished utilizing the C02 laser. Carcinomain-situ and Ti tumors, if limited to the mid true vocal cord,
may be treated in this fashion. An adequate oncologic
operation has been achieved if 2-3 mm of normal
surrounding tissue is excised with the tumor. Under these
circumstances cure rates of 90-95 % can be achieved with
little morbidity in an outpatient setting. An endoscopic
approach is not possible with more extensive vocal cord
involvement. Examples would include the anterior
commissure with direct extension into the thyroid cartilage
( cartilaginous framework of the larynx) or posterior
extension to the arytenoid cartilage. In these cases a
hemilaryngectomy or partial vertical laryngectomy will be
performed. Although airway and deglutition will be
maintained, postoperative hoarseness can be expected.

Surgical Salvage in Laryngeal Cancer
Primary nonsurgical therapy of laryngeal cancers is becom
ing more common. Chemoradiotherapy for advanced
cancer with a goal of laryngeal preservation has become an
accepted treatment option in many institutions. The VA
laryngeal cancer study group recently found a 65%
laryngeal preservation rate in patients otherwise destined
for laryngectomy; 35% required salvage laryngectomy.
Primary radiotherapy is frequently preferred for early
lesions, particularly tumors not easily amenable to
endoscopic excision. When local or regional failure occurs
in these patients, surgical salvage remains the best
treatment option.
Unfortunately, patients who fail initial nonsurgical therapy
may require more extensive salvage operations than if
primary surgical intervention had been performed.
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involvement, unilateral and bilateral, even with very small
primary tumors, occurs frequently. Even in the absence of
palpable lymph nodes, a significant risk of microscopic
disease exists. Because of the frequency of disease in the
neck, a neck dissection is usually a component of surgical
therapy for supraglottic cancer. Unilateral or bilateral
elective neck dissections are performed in most cases in the
absence of clinical neck disease due to the likelihood of
occult spread. A radical neck dissection, which removes all
lymph node bearing tissue along with the interval jugular
vein, sternocleidomastoid muscle and spinal accessory
nerve, is rarely required. More commonly, a selective neck
dissection is performed when no evidence of clinical disease
exists and a modified radical disseciion is performed if
palpable disease exists. The overall morbidity of a neck
dissection is relatively low.

The inability to accurately map the tumor location both
preoperatively and intraoperatively in patients who have
previously undergone chemotherapy or radiation therapy,
usually precludes the ability to perform conservation
laryngeal surgery. Under these circumstances, a total laryn
gectomy is frequently required.

Surgical Treatment of the Neck
A neck dissection or cervical lymphadenectomy is sometimes required in treatment of laryngeal cancer. The glottic
larynx (vocal cords) has very limited lymphatic drainage
and subsequently cervical metastatic disease is uncommon.
About 1 % of Ti and 5-i5% of T3 laryngeal cancers will
have metastatic disease at the time of treatment.
Conversely, the supraglottis and subglottis have extensive
lymphatics. It has been found that up to 40% of Ti, 42%
of T2, 55% of T3, and 65% of T4% supraglottic cancers
have clinical or microscopic metastatic cervical disease
present at time of diagnosis. Cervical lymph node

Michae/R. Nordstrom, MD
Otolaryngology
Head & Neck Surgery

FIRST COURSE TREATMENT FOR LARYNX CANCER
1991 vs. 1996
DISTANT

REGIONAL

LOCAL

IN SITU

TREATMENT

TOTAL

1991

1996

1991

1996

1991

1996

1991

1996

1991

1996

NoTreatment

0

0

0

0

0

0

0

0

0

0

Chemotherapy

0

0

0

0

0

0

0

0

0

0

Radiation

0

i

2

6

2

0

0

0

4

7

Radiation &
Chemotherapy

0

0

0

i

0

2

0

0

0

3

Surgery Only

1

0

2

2

2

0

0

0

5

2

Surgery&
Radiation

0

0

5

2

4

0

0

0

9

2

TOTAL

i

1

9

ii

8

2

0

0
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At St Luke’s Medical Center, between 1 991 and 1 996 there has been an increase in patients treated with radiation only versus combined surgery and
radiation therapy

5 YEAR SURVIVAL AJCC STAGE 1991 LARYNX CASES
(Squamous Cell Carcinoma)
STAGE

NUMBER
OF PATIENTS

SLMC 5 YEAR
SURVIVAL

0

1

100%

1

7

85.7%

2

1

100%

3

5

80%

4

4

50%
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Advances in Microsurgicol Free Flaps For Head and Neck Reconstruction
After almost two decades of use and
experience, microsurgical reconstruc
tion has matured as a widely accepted
and useful method for optimally
reconstructing defects of the head and
neck. Although initially perceived as
an avant-garde technique, the current
perception is that they are work horse
reliable techniques for rebuilding a
Lawrence A. Serkin, MD
wide variety of complex defects in the Dostic and AeconsrucUve
Surgery
head and neck. These include
composite defects of the mandible,
oral cavity and cervical esophagus as well as the face and
scalp. Refinements in free flap techniques have resulted in
more reliable, functional, and aesthetically appropriate
reconstruction. Reliability rates (including our series of 20
cases at St. Luke’s Medical Center) now fall into the
90-95% range.

Mandible DeFects:
Often these defects are compounded by the need for
intraoral lining and/or external skin. Free vascularized
osteocutaneous or myo-osseous flaps from the fibula or
iliac crest provide a reliable solution. The fibula free flap
( peroneal artery) has emerged as a first choice donor site
providing up to 25 centimeters of exceptionally well vascu
larized sturdy bone stock. It’s periosteal blood supply runs
the entire length of the bone, and affords the ability to
make multiple segmental osteotomies, which along with
plate and screw fixation can create a close analogue to the
resected mandible. The donor site heals well and patients
are started on ambulation approximately 5 days post-op.

Free tissue transfer is well recognized as providing healthy,
unscarred, well vascularized tissue to areas of previous
radiation, inflammation, and scar damaged tissue. Even in
severely radiation damaged areas, free flaps have greatly
improved the overall prospects of primary wound healing
and ultimate success of the reconstruction. Similarly,
post-operative radiotherapy has been shown not to
compromise the success of these flaps.
Free flaps allow a one stage reconstruction of large
complex defects, often providing the ablative surgeon more
freedom to perform an adequate wide resection of the
tumor without worrying about “closing the hole”. With
many larger defects a free flap is the only choice for
reconstruction.

Figure 1 A: Deec after excision o o large alveolar ridge
squamous cell corcinomo. Arrow shows Ioerol bone resecUon
morgin.

Studies have shown that free flaps remain highly successful
(greater than 90%) in the elderly, or in patients with
hypertension, diabetes, peripheral vascular disease, or after
pre-op radiation therapy. Suitable recipient arteries and
veins are usually readily available in the neck. Preoperative
angiography of both donor and recipient sites may be
indicated in patients with PVD. Thorough cardiac and
pulmonary clearance evaluation may also be needed.
Refinements in anesthesia management such as, balanced
anesthesia, invasive monitoring, and tight fluid management have contributed to the safe conduct of these
procedures that can last for 8 to 12 hours. Operative time
can be reduced by the use of two teams, so that the donor
flaps can be elevated and prepared simultaneously with the
resection of the tumor.

Peroneal A.

Figure 1 B: Diogrom o Hbulor donor sire.
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Figure 2B: PosLop resorabon oF
contour oF lower Face & mandible.

Figure 2A: Intro-Op after 7 cm segmenoI
mondibuIecomy & immedioe reconsrucbon with
he oseoomized Mbula & pIoe; micro- vascular
onosomosis completed. Arrows show ends o
graft.

Figure 3: Post-op bone scan oF he
Fibula Free Flop (note excellent uptake
and graft vasculariy).

ant

external coverage or muscle for intraoral lining can also be
taken. Both the fibula and iliac crest will readily accept
osteointegrated dental implants.

The iliac crest free flap (deep circumflex iliac artery) is an
excellent alternative donor site for vascularized bone. It
can provide up to 14 centimeters of bone length. Skin for

Figure 4B: Post-op Panorex after anterior mandible & Floor oF
mouth resecUon & immediate reconsrucUon with iliac crest
oseocuaneous Free Flap.

Figure 4A: Iliac crest donor sire diagram. Taking only he inner
cortex oF bone minimizes Flap bulkiness.

Figure 5: Post-op (1 year)
inraoral view after release
& skin graft oF alveolar
sulcus in preparabon For
dental implants. Speech &
mobility are good and he
mandible remains sabIe.
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Facial DeFects:
The radial forearm free flap is quite useful in facial and
intraoral lining reconstruction. It is highly vascularized,
thin, pliable, hairless, and can be sensate.
Figure 6B:•

Figure 6A:
Long sonding
rodiobon ulcer &
oral cuoneous
Msulo. PoUenl
hod previous left
mondibulecEomy
& radical neck
resedion.

8 weeks post-op

after debride
men &
reconsrucUon o

buccollining &
exernol skin with
rodiol oreorm
free Hop.

The radial forearm free flap is also very useful for floor of
mouth defects and for sensate reconstruction of hemitongue
defects.

CervicaIEsophagus..Hypophorynx DeFects:

Figure 7A:
Shows o prepored
segment o
jejunum o
reconsruc 0 7 cm.
deec o he

The jejunal free flap has become the method of choice for
segmental & large patch defects of the cervical esophagus,
by essentially using a “spare part” of a preformed
muscular-mucosa lined tube (segment of small bowel). It
has proven to be relatively straight forward and highly
reliable (greater than 90%). It has a lower rate of fistula
and stricture compared to tubed pectoralis flaps. The
mortality rate (0-5%) is less than half that of the gastric
pull up procedure. Swallowing is restored in greater than
80% of patients usually within 12 days of the procedure.

cervicol esophogus
ofter resecUon o o
lorge squamous

cell carcinoma.

Some of the more frequently used microsurgical free flaps
for typical complex defects of the head and neck have been
summarized. Better functional and aesthetic results cornbined with high reliability rates have greatly increased the
desirability and indications of these techniques.

Figure7B:
Barium swallow 10
days post-op. Note
upper ond lower
onosomoses ore
poenL
-

Lawrence A. Sterkà, MD
Phrstic and Reconstructive Surgery
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Radiation Therapy For Head and Neck Cancers
near future to allow for faster and more precise planning in
the Radiation Oncology section.

The radiation treatment of head and
neck neoplasia has made significant
technical advances over the last
decade. The general goal of increased
cure rates with decreasing morbidity
is slowly being realized through
research and technical innovation.
These major advancements include:
1) Combined modality treatment, 2)
Williom ]. P00, MD
Treatment planning, 3) Stereotactic
Aodioon Oncology
radiosurgery/radiotherapy, 4) High
dose rate brachytherapy, and 5) Interoperative radiotherapy.
These biological and technical advances have been or are
soon being implemented at St. Luke’s Medical Center. The
following is a brief synopsis of each endeavor:

Stereotactic Radiosurgery and Radiotherapy

The logical outgrowth from improved accuracy in the
treatment leads to the concept of radiosurgery. Originally
developed by Leksell for brain tumors, this method utilizes
a pin-based head frame to fixate the patients skull for one
high dose treatment (1500 to 3000 cGy) for intracranial
tumors. Modifications of this concept lead to the development of a relocatable head frame with dental molds and
plastic casting to refit the patients daily for repeated high
accuracy treatment. A stereotactic radiosurgery system for
brain tumors are now in place at St.Luke’s Medical Center,
a logical extension of this treatment modality will be
towards the treatment of base of skull lesions in the future.

Combined Modality Treatment
High Dose Rate Brachytherapy

The current role of combined modality therapy (chemo
therapy followed by radiation) is primarily for organ
preservation. In several randomized trials, most notably
from the VA study group, laryngeal and oropharyngeal
preservation was possible in selected patients with good
response to chemotherapy. These patients then went on to
receive full course irradiation. Non-responders were
treated with surgery. Despite the encouraging trials from
Radiotherapy Oncology Group (RTOG) on nasopharynx
and the European trial with oral and pharyngeal cancers,
there is no definitive proof yet that chemotherapy definitely
improves survival in most patients with head and neck
cancer. Several randomized trials are asking this question
with newer agents. The addition of newer agents such as
paclitaxel to cisplatin, provide responses that are encourag
ing, but only in a randomized setting will we know
whether this will translate to improved patient survival.

The need for advanced treatment planning, decrease in
hospital stay and radiation safety had lead to the development of rapid treatment of localized tumors by High Dose
Rate (HDR) brachytherapy. Traditionally, the use of
radioactive implants entail fixed activity sources on set
arrays in a limited field. With the acquisition of a high
dose brachytherapy unit, we are now able to offer state of
the art brachytherapy for high rise patients. In the head
and neck, the catheters are still implanted in the operating
room, but the treatments are fractionated over 2 to 3 days,
in twice a day fractionation in the HDR suite. This allows
for more precise control of the treatment and fine tuning of
the dosage delivered to tumor and normal tissue. Our new
HDR unit has been in service for nearly 2 years. Protocols
for head and neck cancers are pending.
lntraoperative Radiotherapy

Intraoperative radiotherapy (IORT) for head and neck
cancer has been implemented at St. Luke’s Medical Center
for several years. The use of IORT increase the options we
have for a difficult resection. With close or positive
margins in which critical tissues cannot be further removed,
a large single dose (1000-1500) can be delivered to the
operative bed. This can be combined with external beam
later for improved tumor control. This concept has been
applied to several patients with close/positive margins or
tumor fixation to critical neck structures at St. Luke’s
Medical Center.

Over the last several years, we have developed a fax
transmission system with medical oncology to coordinate,
lab and diagnostic testing and timing of therapy. This
allows for better patient care and prevents duplication of
procedures when patients receive both chemotherapy and
radiation.
Treatment Planning

Radiation therapy has benefited from the advances in MRI
and CT imaging. The contract between tumor and normal
tissue and neoplasm is more easily enhanced and better
visualized not only in the transverse, but in the sagittal and
coronal planes as well. This is especially true with base of
skull lesions with the detection of neuro-foramina invasion.
In addition, with improved immobilization techniques not
available before, we are able to pinpoint treatment with
multiple fields. This decreases morbidity to the surrounding normal tissues and increases dose to the tumor. A new
three dimensional planning system will be installed in the

The options now available to the oncologist to combat
cancer are ever increasing. With persistence and innova
tion, we can improve the outlook for many patients with
head and neck cancer.
Wi/&imf. Pao, MD
Rac&ition Oncology
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Dental Evaluation and Core oF Head & Neck Cancer Patients
Undergoing Aadiation Therapy
The efficacy of radiation therapy has
been proven over time. However,
before radiation treatment starts, it is
important to assess the dental needs,
and the implications that radiation
therapy will have on the oral cavity.
Radiation effects on the dentition are
dose dependent. However, the
amounts of radiation needed to
combat head and neck cancer are
necessarily high.

5. Trismus (Tightening of Muscles)
Here, instruction early in treatment, regarding opening and
stretching exercises will be very helpful in minimizing
future difficulty with oral opening and closing. Trismus
may not start till 3-6 weeks after initiation of radiation
treatment therefore, it is important exercises start before
early signs of trismus manifest themselves.

6. Osteoradionecrosis
Osteoradionecrosis (ORN) is defined as death of bone after
irradiation and is the most serious post-radiation therapy
complication. Radiation therapy has the effect on bone of
creating a hypoxic, hypocelu1ar hypovascular state that
leads to development of ORN. In view of this state,
osteoradionecrosis should be considered as a life long risk.

Alphonse A. Wisniewski,
DDS, FACD
Director, Dental Aesidency
Progrom

Some side effects of high dosage
radiation in the oral cavity are:
1. Xerostomia (Dry Mouth)
Irradiation has a traumatic effect on serous glands leaving
only mucous glands to supply oral fluids to lubricate the
oral cavity. This results in a drop of pH in the mouth to
below 5.5, which is highly conducive to caries formation.

Considering these potential risks, it is advisable to have a
comprehensive dental exam prior to radiation treatment.
This pre-radiation oral exam is very important in management of possible complications arising from treatment once
it is started. The comprehensive exam should assess the
total oral condition of the patient and usually consists of
five parts; dental exam, radiographic exam, soft tissue
exam, functional exam, and periodontal exam.

2. Mucositis
The first signs of mucositis are a localized whitish
appearing mucosa in the irradiated area. Later it becomes
reddish. Eventually the entire mucosa is involved. These
changes can be seen early in treatment. Mucositis gives
way to colonization of otherwise suppressed normal oral
microflora. The patient becomes more susceptible to
infection from bacteria and fungi, which are opportunistic
invaders under these conditions. Mucositis usually subsides
2-3 weeks after radiation treatment is completed unless a
complicating secondary infection is present necessitating
additional treatment.

1 The dental exam will include a complete charting of the
teeth, including caries and restorations present as well as
the vitality of the teeth present in the mouth. Charting and
evaluation of fixed and removable appliances is also
necessary. Impressions of the upper and lower arches are
also taken to fabricate trays for future fluoride treatment.
.

2. The radiographic exam consists of a full series of
intraoral x-rays. The x-rays will be important in facilitat
ing the discovery and treatment of caries, periodontal
disease, and underlying pathology. A panoramic x-ray
should also be included.

3. Hypogeusia (Taste Loss)
Taste loss can also be noted early in radiation treatment.
This change however is unpredictable. When it does occur,
it can rapidly progress to full loss of taste. However, it is a
temporary change and usually patients recover 4-6 months
following completion of therapy.

3 The soft tissue exam will assess the state of the gum
tissues and oral mucosa prior to initiation of radiation
therapy. It will also serve as an important baseline to
diagnose other problems during the course of treatment.
.

4. Radiation Caries
The reason for high incidence of caries in patients that have
been treated with radiation is dry mouth (xerostomia).
Radiation alone does not have any deleterious effects on
enamel or dental pulps. The decrease in pH as previously
mentioned in the oral cavity and the decreased buffering
ability of saliva helps in the demineralization of hard tis
sues. An increase in the bacterial population in the mouth
also aids in the rapid development of caries. It is also
believed that areas of normal gingival recession existing in
the mouth before radiation therapy are more predisposed
to radiation caries due to the fact that cementum is
considerably less calcified than enamel.

4. The functional exam will look at the state of muscles of

mastication, temporomandibular joint, occlusion, and fixed
and removable appliances.
5. The periodontal exam is necessary to discover active or
underlying periodontal disease, measurement of recession,
pocket depths, areas where bleeding or exudate is present.
A plaque index evaluation should be recorded. Scaling and
root planing where necessary should also be done.
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Osteoradionecrosis is a serious complication of radiation
therapy. ORN develops in 3 to 10% of all irradiated
patients. The important tissues at risk for actual development of ORN from effects of irradiations leading to
necrosis are bone, periosteum and vascular endothelium,
along with connective tissue in mucosa, skin and subcuta
neous tissue. All are made worse by poor oral hygiene,
infection and trauma. Cells that divide regularly are
sensitive to radiation and die a reproductive death shortly
after radiation exposure.

The presence of periodontal disease, abscesses, infections,
therapy
and caries will affect the morbidity of radiation
should be
disease
after
it
Active
is completed.
during and
treatof
beginning
eliminated or controlled prior to the
with
filled
and
ment. Dental caries need to be excavated
be
should
they
restorative material, at the very least
excavated and temporarily filled until permanent
restorations can be placed. This will reduce the amount of
microorganisms in the oral cavity and control disease.
Root canal treatment on devitalized teeth should also be
completed. It is also important to control infections and
periodontal disease. Any extraction that the patient needs
should be done before radiotherapy starts to prevent
surgical intervention during therapy. Extraction of teeth
during radiation should only be done if absolutely
necessary. This is done pre-treatment to reduce the risk of
osteoradionecrosis. For most patients 10-14 days is a
sufficient time for healing of oral tissues after necessary
dental treatment or surgeries. However, slow healers or
patients anticipating to receive high doses of treatment
should be allowed to heal between 14-21 days prior to
radiation treatment.

Post radiation surgery increases the risk of tissue necrosis.
Restorative or endodontic treatment is always preferred to
extraction. When surgery or extraction becomes a
necessity, post-operative managemefit is very important.
Antibiotics should be considered to prevent opportunistic
infections and higher doses than normal may be needed
because of compromised blood supply.
Evidence has been presented that the use of hyperbaric
oxygen therapy (HBO) helps reduce the incidence of ORN
in patients who had teeth extracted before radiation thera
py and had undergone a total of 10 sessions in the HBO
chamber prior to extraction.

By controlling these problems the course of treatment and
the healing of tissues can be better predicted. The patient
should also be started on a daily regimen of dental fluoride
application which he/she will follow as long as teeth remain
in the mouth.

In conclusion, frequent dental consultations and treatment
pre and post radiation therapy have been evidenced to be
invaluable in the control and management of the dental
risks associated with this very important and necessary
oncological therapy.

Upon completion of the dental consultation and treatment
the patient will be ready to start radiation therapy. During
this time, only emergency restorative care should be
attempted, along with palliative care for treatment of
mucositis and oral opportunistic infections. Saliva
substitutes may be prescribed if xerostomia is present.

Alphonse A. Wicniewski DThS MCD
Director, Dental Residency Program

When radiation treatment is completed there are two main
effects tORN and Xerostomia) which should be closely
monitored, for a long period of time, possibly permanently.
Frequent follow up appointments are necessary to
prevent radiation caries and mucositis developing due to
the low pH of the oral cavity, dessication of tissue and
of plaque and bacteria.
accumulation
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The Role oF Chemotherapy in Advanced Head and Neck Cancer
Background

second was a European oncology radiation therapy
consortium (EORTC) study utilizing a similar combination.

Squamous cell carcinoma of the head
and neck remains a significant cause
of morbidity and mortality among
cancers in the United States.
Approximately 5 % of all newly
diagnosed cancers in the United States
arise in the tissues of the head and
neck. Despite increased public awareAober F. Ioylo MD
ness regarding smoking cessation and
Medical Oncology
improvements in diagnostic methods,
more than 2/3 of these patients will present with locally
advanced disease at the time of diagnosis. As with many
cancers, tumors detected early with locally advanced
disease at the time of diagnosis. As with many cancers,
tumors detected early and treated with either surgery or
radiation alone may be expected to be cured in 80%-100%
of the cases, and this treatment remains the standard of
care for patients with early disease. However, in patients
with advanced disease, treatment with combined radiation
and surgery has not changed the overall poor outcome in
these cases over the course of many years. Patients who do
not respond undergo extensive surgical procedures that
result in a significant morbidity and reduced quality of life.
For this reason, continued interest in organ preservation
and alternative methods to control advanced squamous cell
carcinomas of the head and neck have been sought and
studied over the past several years.

VA Cooperative Study

The VA cooperative study was one of the first large randomized trials involving patients with resectable squamous
cell carcinoma of the larynx, which utilized a branching
scheme to evaluate treatment response in patients with
these tumors. In their series, the investigators treated these
patients with induction chemotherapy using 5-FU and
cis-platinum for two cycles. Patients who achieved a
substantial response then received a third cycle of
chemotherapy, while those that did not were then treated
with immediate surgical resection. In the responding
group, patients were radiated following completion of the
three induction cycles of chemotherapy and observed
following definitive radiotherapy. Those that relapsed
following such therapy went on to salvage surgery as
indicated and as practical.
The VA cooperative study yielded several interesting results,
the first of which was a very high response rate to the
induction chemotherapy treatment, with 84% of patients
responding to two cycles of chemotherapy including 25%
who were responders; 9 8 % of the patients then went on to
receive a third cycle of chemotherapy with only two
patients having tumor progression. The toxicity of the
protocol was manageable when given in conjunction with
adequate support. A quarter of the patients did have signif
icant mucositis and/or diarrhea during chemotherapy, but
only a small percentage were life threatening and were
successfully treated with hydration.

Modern day chemotherapy for squamous cell carcinoma of
the head and neck has been studied and developed over the
past two decades. The initial trials for chemotherapy and
attempts to facilitate organ preservation was originally
pioneered by Al-Sarraf and colleagues at Wayne State
University. In a series of phase II and III trials published in
the 1 980’s, they demonstrated the combination of cis-plat
mum and 5 ftuorouracil (5-FU) was effective in inducing
complete remissions in patients with locally advanced and
previously untreated squamous cell carcinoma of the head
and neck. In their sequential clinical trials a 54% complete
response rate and a 93% overall response rate was
observed in patients using this combination. As the dose of
5-FU was decreased, the response rate decreased as well.
Recently, however, a randomized trial has shown a
significant increase in overall survival in patients with
unresectable disease treated with induction chemotherapy
as opposed to standard therapy. The addition of radiation
therapy to this regimen seemed a logical next step in organ
preservation, because of the risk of locally recurrent disease
in patients treated with induction chemotherapy alone.

Survival and Disease Free Survival

Patients have been followed, at the time of the last reports,
with a median follow-up of 46 months. Patients who had
a complete clinical response to chemotherapy had a signifi
candy better disease free survival than patients with any
clinical evidence of residual disease, suggesting that both
disease free and overall survival is substantially affected by
chemotherapy. Patients rendered disease free by radiation
therapy did not experience a survival advantage over those
who were disease free following chemotherapy.
One of the major concerns about this approach to treating
patients was whether the treatment would adversely
inftuence salvage radiation therapy, should it be needed
subsequently. In the VA cooperative study however, there
appeared to be no adverse outcomes or any increase in
complications in the group of patients who had undergone
chemo/radiotherapy compared to patients who underwent
traditional surgical procedures.

For this reason, two large cooperative oncology trials were
begun to evaluate the result from a combined modality
therapy with a goal of organ preservation. The first was a
VA cooperative study which was initiated in 1984. The

Response by Site of Disease

Several studies have evaluated the responsiveness of tumors
in various sites in the head and neck region to combined
18

fractionation or combinations of radiation and
chemotherapy may prove beneficial in this regard as well.

modality therapy. Higher rates of responses to
chemo/radiotherapy in the upper oropharynx have been
reported in some circumstances. In the VA cooperative
study, the response rates to treatment were similar in the
supraglottic area as well as the larynx and hypopharynx,
suggesting that patients in both areas might be benefited.

While distant disease was substantially reduced in patients
in these series, micrometastatic disease remains a significant
problem in squamous cell carcinoma. New and more
effective combination chemotherapy regimens are being
evaluated. The MD Anderson Cancer Center has been
evaluating the combination of cis-platinum and 5-FU with
the addition of leucovorin in an attempt to improve
response rates. While toxicity was increased in this group,
the results appear to be somewhat superior to those
achieved with cis-platinuml5-FU alone. Paclitaxel and
other newer agents have shown substantial activity in
metastatic squamous cell carcinomf of the head and neck.
These newer agents may prove beneficial in a sequential
fashion, when used with more conventional platinum
induction chemotherapy regimens. Further clinical trials in
this area are being formulated at this time.

Since the goal of the study was organ preservation, it is
worthwhile to evaluate those results. In 64% of the
patients, the larynx was preserved. Out of 107 patients, 59
underwent total laryngectomy, 30 before definitive radiotherapy and 29 after radiation therapyc Eighteen of the 29
underwent laryngectomy after a planned laryngoscopy and
biopsy confirmed the presence of persistent tumor 12 weeks
after completion of radiation therapy. The rate of salvage
laryngectomy for persistent disease before radiation was
29%, and the rate of salvage laryngectomy for late
recurrence was 7%. In patients who underwent
chemotherapy, the estimated rate of larynx preservation
after two years was 66%, thus the majority of such patients
did achieve the stated goal of preserving laryngeal function
without jeopardizing survival or disease free survival.

Conclusion

The goal of organ preservation in patients with cancer of
the head and neck remains an important one and appears
to be achievable in a substantial percentage of patients.
Unfortunately, many patients with these advanced tumors
continue to experience relapses and ultimately die of their
disease. Earlier detection remains the mainstay for treatment of such patients and preventative programs such as
smoking cessation and aggressive care of premalignant
lesions must be encouraged.

Future Direction

Despite the success of treatments outlined above, a substan
tial percentage of patients with head and neck cancer have
either resistant or persistent disease. Several reasons for
this can be found. First, the response to chemotherapy in
particular seems to be strictly dose related. Patients requir
ing a dose reduction experienced a significant decrease in
benefit, when compared to those who received 100% of
their calculated dose. Patients who were elderly or had
poor performance status were less likely to complete the
planned chemotherapy without dose reduction, and therefore were expected to be more poorly. Thus, vigorous supportive care and adherence to dosing regimens seems to be
essential to achieving high response rates in this tumor.
Patients with larger tumors did worse than patients with
smaller tumors, and earlier treatment in this tumor, seems
to be essential to producing a high response rate. The
importance of early diagnosis and treatment of such
patients cannot be underestimated. Local recurrences were
significantly more common in the chemotherapy group
than were distant recurrences, suggesting that more
effective local therapy is needed to preserve rates of organ
preservation. Perhaps newer schemes of radiation

For patients who do develop such tumors, aggressive organ
preservation must certainly be considered. However, newer
agents are clearly needed along with better means to
control local disease, either through more aggressive
radiation therapy or other combined approaches. Of
particular concern is the development of second primary
tumors in such patients often other smoking related tumors
such as those of the lungs and other portions of the aerodi
gestive tree. This emphasizes the importance of prevention
and continued surveillance in this group of difficult
patients.
Robert F. Taylor, MD
Medical Oncology

AJiotion Theropy Oncology Group (RTOG) Protocols for Head and Neck Cancer:
95-01 : Phase III intergroup trial of surgery followed by ( I ) Radiotherapy vs. (2) Radiochemotherapy for resectable high

risk squamous cell carcinoma of the head and neck.
9 1 I 1 : Phase III trial to preserve the larynx: induction cheimtherapy and radiation therapy vs.
cheiotberapy and radiation therapy vs. radiation therapy.
-

If interested in enrolling a patient in a study or would like information
Radiation Oncology, St. Luke’s Medical Center 649-6420.
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please get in touch

concomitant

with Mitchell Pincus, M.D. in

Speech Pathology Intervention in the Head & Neck Cancer Patient
The speech pathologist is faced with
special challenges injthe case of
patients undergoing total laryngectomy,
or the surgical removal of the vocal
cords due to cancer. The communica
tion options following laryngectomy
fall into three groups including
artificial larynges, esophageal speech
and the tracheo-esophageal
puncture/voice prosthesis.

the front wall of the esophagus (food pipe). The puncture
procedure can be done at the time of the laryngectomy or
at any time
four to six
weeks after
the original
surgery.
Following the
puncture, the
patient is then
fit with a
voice prosthe
sis made of
Figure 2 Voice Preshesis
silicone plas
tic. (See figure #2) By covering the stoma and prosthesis
with the thumb, the patient channels exhaled air from the
lungs through the prosthesis and out of the mouth as voice.
Tracheo-esophageal speech tends to be low-pitched and
guttural-sounding, but more natural in quality than voice
with the artificial larynx. Speech therapy is required to
learn care and cleaning of the prosthesis, as well as, refining
speech with thumb occlusion.

Suson Knier, MS, CCC

Artificial larynges are mechanical, battery-powered, hand-held devices that enable the patient to
produce an artificial voice. Artificial larynges may be
placed intra
orally or on
the neck.
(See figure
#1) In the
case of the
neck-type
device, the
speech
pathologist
assists the
Figure 1 ArUMCiQI Larynges
patient in
finding a soft tissue spot that conducts the sound well. The
patient then forms speech with the artificial larynx as the
new sound source. The intra-oral type device involves
articulation around a plastic tube placed in the mouth. As
speaking with a tube in the mouth can be awkward, this
type of device is generally used only initially after surgery
when the patient’s neck is healing.

The voice prosthesis can also be used hands-free with a
tracheostoma valve. The valve fits in the housing that is
adhered around the
stoma with tape and
glue. The valve naturally
opens for breathing and
closes for speech with
changes in air pressure.
(See figure #3)
The speech pathologist’s
purpose with the total
laryngectomy patient is
not
limited to communi
Figure 3 TraCheosoma Valve
cation. The speech
pathologist also provides basic information on stoma care
and other issues relating to adjustment to life as a laryngec
tomee. The patient is also made aware of support groups
and community resources for coping and educational
concerns. In many cases, the speech pathologist organizes a
meeting with a laryngectomee volunteer so that the new
patient can receive information and hope from someone
who has completed the rehabilitation process.

Another post-operative communication alternative is
esophageal speech. Esophageal speech involves learning to
inject and expel air similar to a controlled belch. The
esophagus becomes the sound source in the absence of the
vocal cords. Esophageal speech tends to be a gradual, diffi
cult method to learn. It requires a long-term commitment
to regular therapy and practice, with fluency gradually
building from short words to phrases to sentences and
finally conversation.
In 1978, Eric Blom (a Ph.D. level speech pathologist) and
Marc Singer (a head and neck surgeon) initiated collabora
tion on a third post laryngectomy communication alterna
tive known as the tracheo-esophageal puncture. The punc
ture involves creating a second opening located at the top
of the stoma (or opening for airway in the patient’s neck)
that goes through the trachea (windpipe) and ends inside

Susan Knki, MV, CCC
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Management oF Swallowing Disorders
The patient may be able to safely tolerate food/liquid with
possible food texture adjustments and/or with use of
compensatory maneuvers. Further evaluation may be
needed to objectively assess swallowing via videofluo
roscopy swallow evaluation or Fiberoptic Endoscopic
Evaluation of Swallowing (FEES). The videoftuoroscopy is
a radiographic study that is performed in conjunction with
a radiologist. The purpose of this study is to define
anatomic and/or neuromuscular dysfunction, function vs.
dysfunction and parameters of the swallow, such as
efficiency and airway protection, identify therapy
echniques and determine appropriate diet.

Dysphagia or swallowing problems
can occur in various typçs of cancer
and may be a symptom of head and
neck cancer in some patients.
The approach to management of
swallowing disorders represent a
multi-disciplinary team including the
patient, family, physician, otolaryngol
ogist, radiation oncologist, speechllan
guage pathologist, nurse, dietitian and
others.

Janice 5ecreo-PoM,
MS, CCC

The speech pathologist plays an important role in the
assessment and management of swallowing disorders
beginning with the initial consultation and continuing until
the patient receives the least restricted diet/the safest
method of nutrition.

The FEES procedure is an endoscopic exam that is
performed in collaboration with an Stolaryngologist. This
study evaluates swallowing and compensatory techniques
by directly visualizing anatomical structures, including the
larynx. It is useful for patients with postural limitations
who cannot be transported to radiology.

The optimal rehabilitation of swallowing in head and neck
cancer begins before medical treatment. Patients should be
counseled pretreatment by the physician and speech
pathologist. The exact nature of changes that may occur
with a person’s swallowing or speech is often not known in
detail until after treatment. However, the patient should be
told to anticipate the need for some intervention by the
speech pathologist post-treatment.

Therapy may be needed to address symptoms/issues that
may arise post-treatment affecting swallow. Structural
changes, reduced ROM, fibrosis, taste changes, weak/
inadequate swallow, decreased saliva flow with dry mouth
( xerostomia), edema and mouth sores are some.
Active muscle strengthening exercises, taste/temperature
stimulation and compensatory strategies (postural techniques, swallow maneuvers, change in food texture) are
used during therapy to facilitate maximum swallowing
potential.

When healing is completed and dysphagia is suspected, the
speech pathologist is consulted by a physician to begin
assessment of swallowing. A clinical swallow evaluation is
performed by obtaining a thorough case history, performing an oral mechanism exam to determine extent of
limitations of orallpharyngeal muscles responsible for safe
efficient swallowing and presenting trials of different food
textures to determine proficiency of the swallow
mechanism and tolerance for food and liquid. During this
evaluation, it is determined if the patient can safely begin
eating or if they need further evaluation or therapeutic
intervention.

Through collaborative effort from all team members,
patients with head and neck cancer are afforded the
opportunity to return to the least restrictive diet, thus
enhancing quality of life.
Janice Secreto-P/iffi, MS. CCC
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Thyroid Cancer
While the history and physical findings are important, most
patients will not have any findings that suggest malignancy
in a thyroid nodule. For these patients, a test is necessary
to determine the likelihood that a nodule is malignant. The
cornerstone of the contemporary work up of a solitary thyroid nodule is the fine needle aspiration biopsy (FNAB).
This procedure as performed by the experienced head and
neck surgeon or endocrinologist working closely with a
cytopathologist has resulted in improved selection of
patients who need surgery. A recent review of FNAB
results indicates a sensitivity of 83 % and a specificity of
92% for the diagnosis of thyroid cancer. The use of
thyroid ultrasound or radioiodine scan in the diagnostic
approach for the patient with a tiyroid nodule is seldom
needed. These tests add unnecessary expense and
contribute little to the diagnosis since they do not
distinguish benign from malignant nodules. The use of
suppressive doses of thyroid hormone in the patient with a
thyroid nodule that has not been evaluated by FNAB is
also not advised.

Thyroid cancer is remarkable for its
overall favorable prognosis relative to
other solid tumors. In the United
States, there are approximately
14,000 new cases of thyroid cancer
annually. This represents only 1.1%
of the new cancer cases diagnosed per
year. Most cases (80-90%) of thyroid
cancer are classified as well-differenti Benjamin ]. Teieiboum, MD
ated. This group includes papillary,
OoIoryngoIogy,
Heod & Neck Surgery
follicular and Hurthle cell carcinomas.
Well-differentiated thyroid cancer is
typified by an indolent clinical course for most patients.
Long term (30-year) survival of 75% can be expected.
Unfortunately, there are cases of well-differentiated thyroid
cancer that behave aggressively, as do the other types of
thyroid cancer. These include medullary thyroid carcinoma
and anaplastic carcinoma which has particularly aggressive
behavior.
The most common presenting sign of thyroid cancer is an
asymptomatic thyroid nodule. Unfortunately, palpable thyroid nodules are common, with a reported prevalence of
5 % The likelihood of a thyroid nodule being malignant is
5-12%. Therefore, the challenge for the physician is to
determine those patients who have a malignant thyroid
mass needing treatment and those patients who have a
benign mass requiring observation only.

The mainstay of treatment for most patients with thyroid
cancer is surgery and postoperative radioiodine ablation.
Total thyroidectomy is the procedure most commonly
performed for well differentiated thyroid cancer. Only
patients with small (<2 cm) papillary cancers and no other
risk factors are considered for subtotal thyroidectomy. The
team approach of the head and neck surgeon and endocri
nologist has resulted in improved outcomes for patients
with thyroid cancer, including lower treatment morbidity
and increased survival rates (94% five year survival).

.

Sometimes there are clues in the history which suggest that
a thyroid nodule may be malignant. These include
evidence of recent growth, pressure symptoms such as
dysphagia, or hoarseness. A history of irradiation to the
head and neck region increases the risk of thyroid cancer.
A family history of medullary thyroid cancer also is a risk
factor. Finally, age and sex of the patient are important
factors. The extremely young or old patient with a thyroid
nodule is more likely to have a thyroid cancer as is a male
older than 60.

Future developments in patient care management will likely
improve the selection process of patients with nodules who
need surgery. Developments in the management of patients
with thyroid cancer will improve the ability to determine
which patients have a cancer that will behave aggressively
and thus demand more aggressive treatment.
BenftiminJ. Teite/baum, MD
Oto/aryngology,

Certain physical findings also may suggest that a thyroid
nodule is malignant. These findings include a nodule that
feels hard, evidence for local fixation, or regional lym
phadenopathy. Laryngoscopy is essential in the evaluation
of patients with a thyroid nodule since the presence of
vocal cord paralysis or tracheal invasion strongly suggests
malignancy.

Head & Neck Surgery
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HISTOLOGY DISTRIBUTION
THYROID CANCER
1996

Papillary
Carcinoma,
(Folhcular

ar
\

55.2%

t

denocarcinoma

3.5%

FIRST COURSE OF TREATMENT FOR THYROID CANCER
1996 PATIENTS
IN SITU

LOCAL

REGIONAL

DISTANT

UNKNOWN

TOTAL

No Treatment

0

2

1

0

1

4

Subtotal
Thyroidectomy w/
Or w/o LN
Dissection

0

5

0

0

0

5

Subtotal
Thyroidectomy w/
Chemotherapy

0

0

1

0

0

1

Subtotal
Thyroidectomy &
Radioisotopes

0

2

1

0

0

3

Total
Thyroidectomy
wlo LN Dissection

0

2

1

0

0

3

Total
Thyroidectomy w/
Limited LN
Dissection

0

1

1

0

0

2

Total
Thyroidectomy w/
Radioisotopes

0

7

0

0

0

7

Total
Thyroidectomy w/
Limited LN’s &
Radioisotopes

0

1

1

0

0

2

Hormone,
Surgery &
Radioisotopes

0

0

1

0

0

1

Thyroidectomy,
NOS

0

1

0

0

0

1

TOTAL

0

21

7

0

1
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TREATMENT

According to Thyroid Carcinoma, a journal by the American Cancer Sociely the most compelling argument for a total thyroidectomy in papillary
thyroid carcinoma patients is that central neck recurrence is less common after a total thyroidectomy. An exception to this recommendation is The
finding of an occult carcinoma or a papillary Thyroid carcinoma less Than 1 .5 cm. Here at ST. Luke’s Medical CenTer The ratio of Total Thyroidecfomies
To subTotal ThyroidecTomies done in 1 996 was 2 To 1.
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Progrom Highlights
younger would eventually be randomized into control and
experimental groups. Women in the experimental group
will have a computer installed in their home and will have
access to CHESS in addition to all the standard support
services available to patients with breast cancer. The
control group will have access to standard support services
and will receive a copy of Dr. Susan Love’s Breast Book.
Women participating in the study will be asked to complete
questionnaires at the time of enrollment and 2, 5 and 8
months after enrollment. The questionnaire collects
information about areas such as the woman’s health status,
mood, support and relationships.

Comprehensive Health
Enhancement Support System
(CHESS)
Breast cancer often creates a crisis for
a woman and impacts many aspects
of her life. Health care providers
have a limited amount of time to
convey information and the woman
may face other obstacles in getting
information, social support and help
with decision making.

\J
Kohy Schroeder, AN
Breos Core Program
Coordinoor

Comprehensive Health Enhancement Support System
(CHESS) is a computer-based system that uses expert
systems, computer-mediated communication, data bases
and an easy-to-use interface to provide information,
decision analysis and social support services to women with
breast cancer. This system provides women supplemental
information and support from more traditional sources
such as health care professionals, written information and
support groups.

At the completion of this study we will have answers to
questions about the impact accessAto CHESS has on quality
of life in women with breast cancer. We believe this study
will demonstrate that access to CHESS as part of the
services offered at St. Luke’s Medical Center will have a
positive effect on quality of life for women with breast
cancer.
For more information about CHESS, please call St. Luke’s
Breast Care Program at 649-7605.

St. Luke’s Medical Center offered women with newly
diagnosed breast cancer the opportunity to participate in a
study of the CHESS system. One hundred newly diagnosed
women with Stage 0, 1, 2, or 3 breast cancer age 60 and

Kathy Schroeder, RN
Breast Care Program Coordáiator

ultra-high doses of chemotherapy; and 3) adoptive
immunotherapy involving multiple infusions of the patient’s
own activated killer T cells and interleukin 2 (an immune
protein that has anti-tumor activity) to accelerate immune
recovery and enhance anti-tumor effects. The T cells are
triggered to grow and kill by stimulation with monoclonal
antibody. The clinical trial has both FDA and St. Luke’s
Medical Center Human Research Board approval and is
supported in part by a grant from the American Cancer
Society. This is the only clinical trial using activated T cells
and PBSCT in the world for breast cancer.

Combination Immunotherapy
and Peripheral Blood Stem Cell
Transplantation For Women with
Stage Ilib and Metastatic Breast
Cancer.
The incidence of breast cancer among
US women is one in eight. For breast
cancer patients with distant
metastases, even when treated with
Lawrence G. Lum, M.D.
ScienUhc DirecMc
autologous peripheral blood stem cell
Immunoheropy
transplantation (PBSCT), the
long-term cure rates are poor. This
outcome is likely due to tumor cells that are reinfused with
the PBSCT and/or persist in the patient after chemotherapy.
Since higher doses of chemotherapy may lead to organ
dysfunction, non-toxic approaches are needed to “mop up”
the cancer cells. For this reason, the ABMT Program at St.
Luke’s Medical Center pioneered a new treatment protocol.

The clinical trial continues to accrue patients. The results
are encouraging with more than 8 patients entered into the
study. Although it is too early to draw conclusions,
infusions of activated T cells have gone smoothly without
any major side effects, and several women have remained
free of breast cancer for more than a year. We are gratified
that this non-toxic immunotherapy treatment combination
with PBSCT can be provided as an alternative to women
with advanced breast cancer.

The treatment under this protocol is a unique combination
of: 1) very high doses of chemotherapy to maximize killing
of cancer cells prior to stem cell rescue; 2) PBSCT to rescue
the patient’s bone marrow function from the effects of the

Lawrence G. Lum, MD.
Scientific Director, Immunotherapy
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Program Highlights
Pioneer Newsletter

The Zeiss MKM System

In 1996, A hospital-wide newsletter was created to educate
and inform physicians, nurses, and ancillary staff about the
clinical research being conducted at St. Luke’s Medical
Center. This newsletter, called the Pioneer, will be
published quarterly. The first issue was dedicated to
research being conducted at St. Luke’s to improve the care
and outcomes of patients with cancer. This newsletter will
be distributed to healthcare providers throughout southeastern Wisconsin to help them assist their patients in
making informed decisions about their health care. Copies
of this newsletter can be obtained through the Vince
Lombardi Cancer Hotline at 1-800-252-2990.

In 1996, St. Luke’s Medical Center Neurosurgical Service
was proud to introduce the Zeiss MKM System Stereotactic
Microscope. This ultimate neurosurgical tool has opened a
new dimension in the treatment of patients with benign or
malignant brain tumors and other brain lesions. The
MKM System combines the improved visualization of a
microscope and the navigational information and guidance
of computer-assisted stereotaxis into a single device.
The MKM System has many advantages over other treatment approaches. For the patient it allows the smallest
possible craniotomy and brain incision, less discomfort and
pain, a more complete excision of tumor, less risk to
surrounding tissue and structures and shorter hospital
stays. For the neurosurgeon it allows the lesion to be
located and approached with ease and allows for clearly
determined boundaries and identification of structures that
must be protected. Advantages for third party payers are
that the patient has less invasive surgery with fewer
complications and shorter ICU stays and hospitalizations
allowing the patient to return to work sooner.

CancerHeip A Computer Program
-

Dedicated on May 17, 1996 in memory of Sandra Davies
by her husband , Mark, and their children, the CancerHelp
computer system is an interactive, touch-activated program
that requires no typing skills or previous computer
experience. This system has the ability to print Physician
Data Query (PDQ) information on cancer treatment.
CancerHelp provides a computerized link with the PDQ
service of the Cancer Fax Line at the National Cancer
Institute through the use of a CD ROM system. PDQ
patient information informs the user about warning signs
of cancer and provides information on current treatments
for most cancers. This information is reviewed and
updated monthly by cancer experts. PDQ information is
intended to assist patients in discussing treatment options
with their physicians. CancerHelp is also available in the
patient/community education resourse area of the Vince
Lombardi Cancer Clinic- Slinger site and the Vince
Lombardi Resourse Center at the Eastern Wisconsin
Regional Cancer Center in Sheboygan.

The Neurosurgical Service at St. Luke’s Medical Center is
the first in the state of Wisconsin to acquire the MKM
System, an instrument of unparalleled technology.
St. Luke’s Medical Center once again continues its
commitment to excellence.

Prostate Cancer Education Video
St. Luke’s Medical Center and the Foundation For
Informed Medical Decision Making, Inc. have created an
educational video entitled “The PSA Decision- What You
Need To Know.” The video, featuring Dr. Stuart Fine, a
urologist on staff at St. Luke’s, was developed through the
financial support of an anonymous donor whose goal was
to men about prostate cancer. It explores options for early
detection of prostate cancer, in particular, the Prostate
Specific Antigen (PSA). The 15 minute video approaches
the screening of prostate cancer from a personal and
unique perspective. The Vince Lombardi Cancer Hotline
will be used as a vehicle in disseminating copies of the
video to physician offices and setting up viewing times and
locations for interested consumers.
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supporters or kids
trying to quit. The
program educates them
about the dangers of
smoking, addressing
situations that foster
smoking habits and
how to substitute them
with nondrug/tobacco
behaviors. The goal
for 1998 is to package
the program and pilot it in
three other schools.

The NICO Free Teens Project
One of the goals of the American Stop
Smoking Intervention Study (ASSIST)
for a tobacco free Wisconsin is to
reduce the smoking among
adolescents aged 12-1 8 to half of the
1989 level (of about 31 % high school
seniors) by the year 1998. St. Luke’s
Moro Bjegovch, RN, MSN
Medical Center Cancer Services staff
Cancer Services Director
partnered with the American Cancer
Society, West Allis Health Department,
and Nathan Hale High School in creating a youth smoking
cessation pilot program during the Fall of 1996. This
program, entitled “Nico Free Teens”, is a peer led program
mentored by St. Luke’s Medical Center Cancer Services
staff and members of the aforementioned agencies. Teens
who have never smoked or who have quit are supporting
those who are trying to quit. Weekly agendas are
developed by the program staff
and gone over with the
nonsmoking peers to use
as a guide for them to
use during their
meeting with their
smoking peers (see
below). Forty four
teens at Nathan Hale
High School have
participated in the
program as peer

Facts about teen smokers in Wisconsin:

I

.

Each day 120 children try their first cigarette.

I

About 109,000 youths, between the ages of 11 and 17,
smoke regularly.

.

Of teen smokers, half will become addicted, and half of
those addicted will die of diseases caused by smoking.

.

More than 8,000 people in Wisconsin die from tobacco
related illnesses each year.

.

More than half of adult smokers began smoking before
the age of 14.
Marri 3yegouich, RN, MSN
Cancer Serziices Director
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I 996 Annual Aeport For Vince Lombordi Cancer Clinic
all Vince Lombardi staff and coordinators who had worked
with the patient. This special gift represents the spirit of
life and hope and the many days filled with sunshine that is
wished for all patients.

The Vince Lombardi Cancer Clinic
(VLCC) has adopted a swpe of care,
which
states that the clinic provides a
multidisciplinary approach to cancer
care with emphasis on physical,
emotional and spiritual support in a
highly specialized environment. The
focus of cancer management may vary
from aggressive treatment with the
PoUy Abello, AN, BSN
intent to cure, to symptom manageMonoqer VLCC
ment or palliative care. This accountability based system provides consistency in client care and
better ensures that appropriate resources are utilized.
Personalized, cost-effective, quality care is always the goal.

The second program is called Hats with Heart. Emotional
well-being is closely tied with one’s perception of appearance. To facilitate patients to achieve normalcy in their
lives, the issue of hair loss needs to be addressed. Hats with
Heart are designer turbans, scarves, berets and hats that are
available in the clinic for the patients and are often seen as
a nice alternative to wigs.
The VLCC patients and staff enjoyed a bigger surprise than
the Green Bay Packer’s Superbowl vfctory this past year
when Packer player Reggie White and his wife made an
unplanned visit to the clinic. They added excitement and
fun to what would have been a routine treatment day for
the patients. Personalized care doesn’t get any better than
that.

In keeping with the goal of personalized care, the VLCC
developed two new programs in 1996. The first is a gift
program for patients completing treatment. Patients who
“graduate” from the bone marrow transplant program or
from a particular treatment regimen receive a T-shirt, which
depicts a beautiful, bright sun with the word “LIFE”
written underneath. The T-shirt is presented to patients
along with a congratulatory certificate personally signed by

Patty Abella, RN, BSN
Managei VLCC

Spiritual Corner
significant others; 141 patients and 101 spouses!significant
others completed the surveys. Chaplain tasks most fre
quently requested by patients were: visiting periodically
(85.8%), visiting when the patient is alone (77.3%), and
listening (73 %). Chaplains tasks most frequently requested
by spouses!significant others were: visiting periodically
(83.2%), listening (77.2%), and visiting when the patient is

During 1996 the Pastoral Care
Department conducted three research
projects.
1 “A Survey of the Role of the
Chaplain with Oncology and
Cardiology Patients”
.

2. “Spiritual Well-Being and Hope in
Cancer Patients”

3 “Does Structured Instruction
Influence Cancer Attitudes and
Beliefs?”

alone (75.2%).
Rev. Mordo Mohno
Cancer Services 5a
Chaplain

The survey tool was also sent to 531 area clergy and
pastoral ministers; 230 surveys were completed. Chaplain
tasks most frequently requested by pastors were: notifying
the congregation of the patient’s admission to the hospital
(98.7%), visiting periodically ( 84.8 % ), and listening
(82.6%).

.

The results of the first one will be described in this report.
The results from the other two studies will be forthcoming.

These survey results raised the importance of chaplain visits
to cardiology and oncology patients and their pastors!
pastoral ministers. The results also highlighted the need for
communication to the local congregation (upon patient
request) when a patient is admitted to the hospital.

The study, “A Survey of the Role of the Chaplain with
Oncology and Cardiology Patients”, was completed in
order to research the specific ways hospital chaplains can
support hospitalized oncology and cardiology patients.
The principal investigators were Rev. Marcia Marino,
Cancer Services Staff Chaplain, and Rev. Harvey Berg,
Director of Pastoral Care.

All three research projects were supported by a grant from
the Vince Lombardi Cancer Clinic Research Advisory
committee at St. Luke’s Medical Center.

A survey tool which listed the specific tasks of a hospital
chaplain was sent to 611 patients and their spouses!

Ret’. Marcri Maráro
Cancer Serziices Staff Chaplaiii
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St. Luke’s Cancer Services Support Groups
Education, inspiration and a sharing of experiences for
people whose lives have been touched by cancer.

Ovarian Cancer Awareness Group
For women who are at risk for or have been diagnosed
with ovarian cancer. Health care professionals offer educa
tional information on risk factors and the latest treatment
options, and provide an opportunity for communication
and emotional support.

Your Caring Connection
For people who have experienced cancer their families and
friends. Topics of discussion focus on many aspects of
cancer education, with presentations given by St. Luke’s
doctors, nurses, social workers, psychologists, chaplains,
and other health care professionals.

Meets the first Tuesday of each month from 6:30 to 8 p.m.
in the Vince Lombardi Cancer Clinic at St. Luke’s Medical
Center.

Meets the second and fourth Monday of each month from
6:30 to 8 p.m. in the Radiation Oncology Conference
Room at St. Luke’s Medical Center. Registration is not
required.

The Kid’s Connection
For children ages 5 through 1 8 whose parent or loved one
has cancer. Participation helps children learn about cancer,
express their feelings and discuss’their experiences with
other children. Sessions are facilitated by St. Luke’s child
life and cancer nursing specialists.

Make Today Count
For people with cancer or other life-threatening illnesses.
Co-sponsored by St. Luke’s and the American Cancer
Society, this support group helps improve the quality of life
for people with a serious illness through positive support
and open communication.

Meets for four weekly sessions at St. Luke’s Medical
Center. Registration is required.
The ABMT Support Group
For people who have undergone an autologous bone
marrow transplant (ABMT). Facilitated by members of the
St. Luke’s ABMT team, this group offers support and a
wealth of educational information in a nurturing
environment.

Meets the fourth Thursday of each month from 7:30 to 9
p.m. at Cudahy United Methodist Church, 5865 South
Lake Drive.
Breast Friends Breast Cancer Support Group
For women who have been diagnosed with breast cancer,
their families and friends. Sessions are facilitated by the
coordinator of St. Luke’s comprehensive breast care
program, who is a registered nurse.
-

Meets in the Vince Lombardi Cancer Clinic at St. Luke’s
Medical Center. For information on dates and times,
please call the Vince Lombardi Cancer Hotline at 649-7200
or 1-800-252-2990.

Meets the last Tuesday of each month from 6 to 8 p.m. in
the Vince Lombardi Cancer Clinic at St. Luke’s Medical
Center.

Look Good. Feel Beffer
For people who are undergoing cancer treatment. This
program presents techniques to help people gain control
and even triumph over the cosmetic side effects of treatment. Topics of discussion and demonstration include hair
styling, wigs, scarves, nails, skin care and make-up. This
program is sponsored by St. Luke’s Medical Center and the
American Cancer Society in affiliation with experts from
the cosmetics industry.
.

Prostate Cancer Support Group
For men who have experience prostate cancer, their families
and friends. Sessions are facilitated by a clinical nurse
specialist, chaplain, physician and/or other health care
professionals.

Meets the first Thursday of each month from 1 to 2:30
p.m. or 7 to 8:30 p.m. at St. Luke’s Medical Center.

Meets six Mondays per year from 1 to 4 p.m. Call
649-7200 or 1-800-252-2990 for specific dates and to
register.

Meets the first Wednesday of each month from 7 to 8:30
p.m. at St. Luke’s New Berlin Health Care Center, 14555
West National Avenue.

All of the St. Luke’s support groups listed above were
organized specifically to support people with cancer and
their families and friends. There is no charge for attending
these groups. Patients and families are encouraged to
attend as many sessions as they wish.

Meets the first Wednesday of each month from 10 to 11:30
a.m. at Aurora Medical Group Northshore, 8706 North
Port Washington Road.

For more information about St. Luke’s cancer support
groups, please call the Vince Lombardi Cancer Hofline at
649-7200 in Milwaukee or 1-800-252-2990 outside
Milwaukee.
28

ABMT Weekly Support Group
families enjoy the confidential meeting space and the
opportunity to share their feelings about cancer and cancer
treatment.

Every Tuesday patients who have
undergone an Auto1ogou Bone
Marrow Transplant (ABMT) come to
the Vince Lombardi Cancer Clinic for
follow-up physician visits and testing.
The ABMT Weekly Support Group
meets on Tuesday mornings as one
way of further meeting the needs of
patients who have completed their
inpatient stays.

The ABMT Weekly Support Group is a place where
patients continue their journey of healing through the
sharing of experiences, stories, laughter, and tears.
The ABMT Weekly Support Group agenda is determined
by the needs and requests of the patients. Now and then, a
patient who has completed his or her treatment will visit
the group. Also, the group occasionally plans to have a
guest speaker. The ABMT Coordinators and the Cancer
Services Staff Chaplain facilitate the group at the present
time.

The format of the group is flexible.
Patients may temporarily leave the
group meeting to have lab work or to
see their physician; they then often
return for the completion of the
meeting.
The ABMT Weekly Support Group
offers patients and families a place in
which they can share experiences,
offer and receive encouragement, and
learn from each other. Patients and

Kiicten Gleesing, R.N, BS.N
ABMT Coordbzator

Ret’. Marcrz Marázo
Cancer Services Staff Chaplain
Rev. Motcia Morno,
Cancer Services 5oF
Chaplain

Medicol Grond Rounds
patients receiving transplants from unrelated donors. Bone
marrow transplantation has been successfully used to treat
previously fatal diseases such as leukemias, aplastic anemia,
lymphomas, and congenital immune diseases. New drugs
have been and continue to be developed to prevent lifethreatening reactions and infections in patients who have
received transplants. The presentation was highlighted
with his personal stories about physicians, researchers, and
patient heroism. Dr. Thomas was awarded the Nobel Prize
for Medicine in 1990 based on his over 25-years of
pioneering work in bone marrow transplantation.

Bone Morrow Transplantation:
Past, Present & Future
E. Donnall Thomas, M.D. was a guest at St. Luke’s
Medical Center in April of 1996. His Grand Rounds
presentation was on the history of transplantation,
especially clinical bone marrow transplantation. He
recounted the trials and tribulations of the earliest attempts
and research. Initial successes in animals and humans were
among identical twins and immunologically-matched
siblings. Subsequent advancements in immunology, particu
larly in the area of tissue typing, improved survival among
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St. Luk&s Cancer ConFerences
April 24, 1996

January 4, 1996

Breast Cancer

Paffiation of Bone Pain Associated with
Advanced Prostate Cancer

Wendy Mikkelson, MD
Health Science Building, Classroom 3

James Kozlowski, MD

May 2, 1996

January 24, 1996

Multiple Myeloma
J ames R. Berenson, MD

Head and Neck Cancer
Michael Nordstrom, MD
Health Science Building, Classroom 3

June 1, 1996

What’s New in Pancreatic and Bffiary Cancer

January 31, 1996

Oncology
J onathan Treisman, MD

October 16, 1996

Breast linaging and Intervention

Health Science Building, Classroom 3

William Goell, MD
Mark Wenzel, MD

February 3, 1996

Head and Neck Cancer Update
Michael S. Benninger, MD, Robert L. Foote, MD
Everett E. Vokes, MD
Schroeder Fellows Program in Clinical Oncology

October 26, 1996

Surveillance, Surgery, Seeds and Sexuality:
What’s New in Prostate Cancer?
Joseph E. Oesterling, MD
Peter D. Grimm, MD

February 22,1996

Debate Surrounding the Role of Chemotherapy
for the Treatment of Non-Smali Cell Cancer of
the Lung

November 21, 1996

Gene Therapy: Trials, Tribulations, and the
Future

Everett E. Vokes, MD
Stiemke Auditorium

R. Michael Blaese, MD
Schroeder Fellows Program in Clinical Oncology

April 11, 1996

Bone Marrow Transplantation: Past, Present
and Future
E. Donnall Thomas, MD
Schroeder Fellows Program in Clinical Oncology
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Schroeder Fellows Progrcm

_i

I

The Cancer Services staff at St. Luke’s Medical Center is
committed to meeting the needs for education, support and
coordination of care of men with prostate cancer. The mission of St. Luke’s program for men with prostate cancer is
to provide comprehensive, state-of-the-art, individualized
care which addresses physical, psychological, social and
spiritual needs. The team focuses on maximizing a man’s
quality of life and return to independence. The goals of the
Prostate Cancer Program are: 1 ) to provide treatment
education, which allows men to make informed decisions
about their cancer care, 2) to provide ongoing coordinated
personalized, interdisciplinary care to men and their
families through all phases of treatment and followup and
3 ) to make expert cancer treatment afid consultation
services available to men with prostate cancer, as well as
their physicians throughout Southeast Wisconsin.

Surveillance, Surgery, Seeds and Sexuality:
What’s New in Prostate Cancer?
on October 26, 1996, Dr. Joseph E. Oesterling & Dr. Peter
D. Grimm were guest speakers at St. Luke’s Medical Center
sponsored by the Schroeder Fellows Program in Clinical
Oncology. Dr. Joseph E. Oesterling, Chief of Urology at
the University of Michigan discussed the role of Prostate
Specific Antigen (PSA) testing in the diagnosis and management of prostate cancer and current surgical approaches to
prostate cancer. Dr. Peter D. Grimm, Radiation Oncologist
at Northwest Tumor Institute in Seattle, Washington
reviewed prostate seed implants as a radiation therapy
approach to prostate cancer. Dr. Stuart W. Fine, Urologist
on staff at St. Luke’s Medical Center discussed issues
related to sexuality, impotence and incontinence for
patients with prostate cancer.

functioned well enough to correct the inherited metabolic
defect in these T cells. In collaboration with W. French
Anderson and Steven Rosenberg, his laboratory carried out
the first clinical application of retroviral-mediated gene
transfer in humans, which demonstrated the feasibility and
relative safety as well as confirmed that NeoR gene marked
T cells could be used for clinical applications in cancer
patients. In 1990, Dr. Blaese and his colleagues initiated
the first gene therapy trial in children with ADA-deficiency
severe combined immunodeficiency (SCID). More recently,
he and his colleagues have investigated gene therapy in the
treatment of AIDS and brain tumors.

Gene Therapy: Trials, Tribulations, and the Future
R. Michael Blaese, M.D., Chief, Clinical Gene Therapy
Branch, National Human Genome Research Institute,
National Institutes of Health was a guest speaker at St.
Luke’s Medical Center in November, 1996. Dr. Blaese is
widely recognized for his contribution to the development
of gene therapy as a clinically useful procedure. His lab
perfected the techniques and performed the essential pre
clinical studies in human T cells using retroviral-mediated
gene-transfer to insert genes. In 1985, they introduced the
gene for adenosine deaminase (ADA) using a retroviral
vector into I cells from patients that were deficient in the
ADA gene. In the laboratory, the transferred genes

Schroeder Fellows Program Head and Neck Cancer
An Update

The role of radiation therapy in the treatment of tonsil and
tongue base cancer was discussed by Dr. Robert Foote. Dr.
Foote, Associate Professor of Radiation Oncology at the
Mayo Medical School, addressed the question “Should
radiation therapy be used as primary treatment, as adjuvant
to surgery or not at all in tonsil and tongue base cancer?”
Dr. Everett Vokes, Professor, Medical and Radiation
Oncology at the University of Chicago, presented the role
chemotherapy plays in the treatment of head and neck
cancer.

-

On February 3, 1996, St. Lukes’ Head
and Neck Cancer Services along with
the Schroeder Fellows Program in
Clinical Oncology offered a Head and
Neck Cancer Update. Three nationally
recognized physicians in the treatment
of head and neck cancers addressed an
audience of physicians, nurses and
other health care professionals.

Participants in this program found the information highly
beneficial and thought provoking. Many would like to see
future programs offered for continuing education.

Susan Nuccio, RN, MSN
Head & Neck Cancer
Coordaaor

Dr. Michael Benninger Chairman of
the Department of Otolaryngology
Head and Neck Surgery at Henry Ford Hospital in Detroit,
spoke on the short stay surgery for head and neck cancer.
-

Susan Nuccio, RN, MSN
Head & Neck Cancer Coorthiator
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Tumor ConFerences
residents, nurses and other allied health professionals. The
exchange of information provides an opportunity to teach
and learn for all those who attend.

General multi-disciplinary Tumor Conferences are held
every Monday of each month at St. Luke’s Medical Center,
with the third Monday of every month, dedicated to Head
and Neck cancers. A general Tumor Conference is held on
the third Friday of every other month at St. Luke’s South
Shore.

The conferences have an average attendance of 44 health
care providers. Attendees include medical and radiation
oncologists, pathologists, radiologists, surgeons, primary
care physicians, specialists, residents, students, nurses,
pharmacists, support staff and other allied health profes
sionals. Physicians are encouraged to present cases of their
own and can schedule a particular case of interest at any
time throughout the year. For more information regarding
Tumor Conference, or to make arrangements to have a case
presented please contact the Clhical Data Registry at
649-6712.

At each Tumor Conference approximately 2-3 cancer cases
requiring diagnostic and/or treatment decisions are presented.
All physicians involved in the cases are invited to attend.
Each conference focuses on the diagnosis, work-up
evaluation, staging, treatment options, rehabilitation and
follow-up of cancer patients. Tumor Conferences provide
an interdisciplinary discussion of treatment approaches and
a statistical review of outcomes and survival. Each
conference serves as an educational tool for physicians,

Tumor Conference- Review of Cancer Sites Presented

Number of Cases

Sitc

.

Head & Neck

21

Lymphoma

‘S

Lung

14

Sarcoma

1%

Brain/CNS

11

Breast

10

Colon

6

Bladder/Urinary Tract

6

Melanoma

6

Prostate

S

Thyroid

S

Esophagus

S

Ovary

3

Rectum

3

Testis

3

Pancreas

3

Bone

3

Benign Conditions

3

Endometrium

2

Unknown Primary

2

Myeloma

2

Kidney

2

Leukemia

1

Penis

1
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Cancer Aegistry Annual Aeport Statistics
recommendation to have a physician advisor for the Cancer
Registry and Dr. Jonathan Treisman accepted the role. He
is available to the Cancer Registry to answer questions on
staging and to serve as an educational reference.

In 1996, the Cancer Registry at St. Luke’s Medical Center
(SLMC) accessioned 1,831 new cases, 177 of which were
St.
Luke’s South Shore (SLSS) campus cases. This reftects a
5.6% increase since 1995. The class of case distribution
revealed 1535 analytic and 296 non-analytic cases.
According to Cancer Facts & Figures-1996 prostate cancer
was, once again, predicted to be the most common cancer
diagnosed in 1996, followed by breast. The five most
frequently diagnosed cancers at St. Luke’s in 1996 were
breast, lung, prostate, skin and colon cancer. Although
prostate was among the top five sites, breast was the most
common cancer diagnosed at SLMC in 1996. The top five
cancers account for 58% of all the cancer cases in 1996.
At St. Luke’s, adenocarcinoma was the most frequent
histology diagnosed in 1996, followed by infiltrating duct
cell carcinoma, squamous cell carcinoma and basal cell
carcinoma.

At the end of 1996 there were over 16,000 cases in the
Cancer Registry data base. Of these, approximately 6,600
were living patients and were currently being followed on
an annual basis by the registry. With the aid of physicians,
office staff, area hospitals and fellow cancer registrars, we
maintained a 96.2% successful follow-up rate. The
remaining 3.8% were considered lost to follow-up, but was
still well within the 10% allowed by the American College
of Surgeons for approved cancer programs.
In 1996, the Cancer Registry responded to 22 data requests
from physicians, administrative staff, cancer support staff
and other requesters for surveys, research, and marketing
purposes. In 1996, we participated in the Patient Care
Evaluation studies for both soft tissue and thyroid cancers.
The Cancer Committee initiated an internal laryngeal
cancer study to evaluate recurrence rates in laryngeal cancer
patients treated with surgery and/or radiation therapy. A
bladder sparing study and an internal breast study
comparing patients treated with a mastectomy vs.
conservative treatment were also conducted.

In January, 1996 Medical Registry Services, Inc. (MRS) for
windows, a PC-based program, was installed as the new
software program for the Cancer Registry. MRS provided
the registry with the ability to create customized reports,
the capability to design customized data collection fields,
the opportunity to create customized follow-up letters, and
overall smooth system navigation. With the new system
installation the Cancer Registry was approved for a new
reference date of January 1, 1985. Therefore only cases
from January 1, 1925 and forward were converted into the
new system. However, prior cases were retained in a database for historical purposes. Follow-up on prior cases
would no longer be done, so survival data would not be
available. The American College of Surgeons Commission
on Cancer released an updated version of their Data
Acquistion Manual, renaming it the Registry Operations
And Data Standards (ROADS) manual, in which the new
guidelines went into effect starting with 1996 cases. In
1996, with the approval of cancer committee, the registry
stopped abstracting local basal cell carcinomas, allowing
them to be accessioned only and staging forms to no longer
be required. In 1996, Cancer Committee made a

The charts and graphs displayed throughout this 1996
Cancer Program Report represent a limited summary of
cancer diagnosis and treatment at St. Luke’s Medical
Center. Comparisons with state and national figures, as
well as narratives, have been provided when available.
This year’s report has a special focus on head and neck
cancer.
For further information, questions, and/or data requests
please contact the Clinical Data Registry at 649-6712.
Sheri Hackbarth, R.R.A.
Cancer Registrar
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Annual Report Statistics

ST. LUKE’S MEDICAL CENTER
VOLUME OF CANCER CASES BY YEAR
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GENERAL SUMMARY STAGE AT DIAGNOSIS ALL 1996 CASES (1831 CASES)
-

Distant 1 7.7%
vn

InSitu
Local
Regional
Distant
Unknown

‘\

1996SLMC

1995W15

5.1%

8.4%
39.7%
21.9%
15.0%
10.6%

43.1%
24.8%
17.7%
9.3%

In Situ

Local
43.1%

According to Cancer Facts & Figures-i 996, only i 5% of lung cancers are discovered with localized disease and 57% of all prostate cancers are
discovered while still localized. At St. Luke’s Medical Center, 22% of lung cancers and 78% of prostate cancers were diagnosed in 1 996 at local
stages, which is comparable to i 995 Wisconsin figures (most current available) of 2i % of lung cancers and 68% of prostate cancers being defected
while still localized. At St. Luke’s in-situ and localized cancers comprised 48.2% of all cases diagnosed in 1 996 with 24.8% and 1 7.7% at regional and
distant stages respectively (These figures include basal cell and squamous cell carcinoma of the skin). On the whole, St. Luke’s figures for the percentage of patients seen at each general summary stage at diagnosis are quite comparable to Wisconsin’s figures.
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Top Five Sites For 1 996 General Summary Stage at Diagnosis
-

SKIN (163 CASES, including 40 Melanomas)

BREAST (301 CASES)

oI sI

In Situ
Local
Regional
Distant
Unknown

1996 SLMC
13.6%
51.0%
32.2%
2.9%
0.3%

1995 WI’
13.5%
51.5%
25.1%
3.9%
6.0%

Percent
5.5%
49.1%
0.6%
2.4%
42.4%

4C
9
80

In Situ
Local
Regional
Distant
Unknown

4
69

LUNG (22$ CASES)

PROSTATE (219 CASES)

22.3%

Unknown 1.3%

Distant
6.4%
Unknown
0.9%

InSitu
Local
Regional
Distant
Unknown

1996 SLMC
0.0%
78.5%
14.2%
6.4%
0.9%

at

1995 WI*
1.0%
68.2%
12.0%
6.1%
12.7%

In Situ
Local
Regional
Distant
Unknown

1995 WI’
0.2%
21.6%
29.5%
35.2%
13.5%

1996 SLMC
0.0%
22.3%
32.4%
44.0%
1.3%

COLON (151 CASES)
Distant

In Situ
Local
Regional
Distant
Unknown

1996 SLMC

1995 WI*

7.3%
30.5%
48.3%
12.6%
1.3%

6.0%
29.7%
40.4%
16.1%
7.6%
..

a_

1 995 Wisconsin figures do not equal 1 00% due to the exclusion of “non-localized” tumors
Wisconsin skin cases are not available to use for comparison.

*
**
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Local
30.5%

SITE DISTRIBUTION

NUMBER OF CASES
MALES
FEMALES

Breast

TOTAL

3

298

301

Bronchus & Lung

133

95

228

Prostate

219

0

219

95

68

163

Skin
Colon

66

85

151

Bladder/Ureter

67

32

99

LymphNodes

36

33

69

Hematopoletic System

30

29

59

Unknown Primary

29

28

57

0

52

52

Kidney/Renal Pelvis

24

24

48

Rectum, Rectosigmoid, Anus

22

19

Pancreas

21

20

Stomach

21

14

35

0

33

33

Thyroid/Endocrine

12

20

32

Esophagus

22

6

28

Brain, CNS, Peripheral Nerves

11

14

25

Cervix

0

24

24

SoftTissue

14

9

23

Larynx

9

5

14

Testis

14

0

14

Liver, Gallbladder & Bile Ducts

9

5

14

Female Genitalia (Vulva & Vagina)

0

8

8

Tongue

6

2

8

Lip, Mouth & Gum

9

Endometrium

Ovary & Unspecified Female Sites

.

41
41

7

2

Bone

3

4

7

Palate

4

1

5

Small Intestine

1

2

3

Eye & Adnexa

2

1

3

Thymus, Heart & Mediastinum

3

0

3

Tonsil

3

0

3

Nasopharynx

0

2

2

Pyriform Sinus

1

1

2

Penis

2

0

2

RetroperitoneumlPeritoneum

1

1

2

Hypopharynx

1

0

1
1

Accessory Sinuses

1

0

Ill-Defined Digestive

1

0

1

Parotid Gland

1

0

1

894

937

1831

TOTAL

According to Cancer Facts & Figures-i 996 regular screening and self-exams can detect cancers of the breast tongue, mouth, colon, rectum, cervix,
prostate, testis and melanoma at an early stage, when treatment is more likely to be successful, These sites include over half of all new cases for
1 996, At Sf, Luke’s Medical Center these cancers accounted for approximately 43% of all new cancers diagnosed in i 996, The most frequently
diagnosed cancers in Wisconsin in 1 995 (most current figures available) for men were prostate, lung, and colon, For women, the most frequent sites
were breast, lung, and colon, This corresponds with the incidence at St, Luke’s Medical Center,
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Annual Aeport Statistics
1996 USA

1996 WISCONSIN

1996 SLMC

(ESTIMATED NUMBERS,
TOTAL CASES 1,359,150)

(ESTIMATED NUMBERS,
TOTAL CASES 27,100)

(ACTUAL TOTAL NUMBER
OF CASES 1,831)

BREAST

184,300 (13.6%)

3,700 (13.6%)

301 (16.4%)

WNG

177,000 (13.0%)

3,000 (11.1%)

228 (12.4%)

PROSTATE

317,100 (23.3%)

7,400 (27.3%)

219 (11.9%)

133,500 (9.8%)

2,600 (9.6%)

190 (10.4%)

-

-

COLORECTAL

-

-

-

SITES

-

It is estmafed that over 1 0 million Americans olive today hove a history of some iype of cancer. About 1 359,1 50 new cancer cases were estimated
to be diagnosed in the U.S. in 1 996. This estimate does not include carcinoma in-situ and basal and squamous cell skin cancers. The incidence of
these skin cancers is estimated to be over 800,000 cases annually. The National Cancer Institute estimates the overall costs for cancer at $1 04 billion.
The cost of cancer screenings. including mammograms, Pap smears, and colorectal exams adds another $3 to $4 billion t9 overall cancer costs, but
reduces suffering and saves lives if cancer is detected at an earlier, treatable stage. St. Luke’s Medical Center’s actual total number of cases is very
comparable to the U.S. and Wisconsin’s estimated number in both lung and colorectal. However, St. Luke’s Medical Center has a higher number of
breast cases and a lower number of prostate cases when compared to the U.S. and Wisconsin numbers.

MOST FREQUENT HISTOLOGIES
DIAGNOSED IN 1996
Number
of Cases
Histology Distribution
Adenocarcinoma
Infiltrating Duct Cell Carcinoma
Squamous Cell Carcinoma
Basal Cell Carcinoma
Epithelial Tumor/Carcinoma
Papillary Transitional Cell Carcinoma
Melanoma/Pigment Nevus
Small Cell Carcinoma
Lobular Carcinoma
Renal Cell Carcinoma
Squamous Cell Carcinoma, Keratinizing
Duct Cell Carcinoma In Situ
Transitional Cell Carcinoma
Papillary Carcinoma
All Others (150 with counts not displayed)

592
192
115
85
62
61
31
27
27
26
25
23
21
12
520
1,831

TOTAL

FIVE YEAR OBSERVED SURVIVAL RATES
ST. LUKE’S MEDICAL CENTER 1991 CASES
Breast

Lung

Prostate

Colon

(193 Cases)

(164 Cases)

(139 Cases)

(88 Cases)

Local

85.9%

34.2%

73.5%

61.9%

Regional

58.2%

15.7%

84.7%

42.6%

0%

4.8%

9.7%

5.4%

STAGE

Distant

St. Luke’s Medical Center rates are based on 1 991 analyfic cases followed through 1 996. Patients lost to follow-up are counted as expired for survival.
Follow-up is based on the date of last contact. Patients are considered “lost to follow-up” if no contact has been able to be made within 1 5 months of
the last follow-up date. Cases that are “lost” remain in the follow-up process until information is obtained or they can be confirmed as deceased.
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Annual Report Statistics
AGE AT DIAGNOSIS
SLMC (1996) vs. STATE OF WISCONSIN (1995)
45%
40%

•=wi

35%
c_)
3O%

1 995 incidence of the
state of Wisconsin (most
current figures available)
showed that individuals
between the ages of 60
and 79 accounted for
53% of newly diagnosed
reportable cancer cases
In comparison, 1996
incidence for St. Luke’s
showed this age group
accounted for 55% of
the newly diagnosed
cases.
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AGE
AGE

SLMC

WI

0 29
30-39
40-49
50-59
60-69
70-79
80+

2.7%
4.8%
9.2%
13.6%
27.2%
28.2%
14.3%

3.6%
4.3%
8.2%
13.4%
24.7%
28.7%
17.1%

-

AGE AT DIAGNOSIS BY GENDER
0 29
-

30

-

39

40 49
-

NUMBER OF CASES
26 Males
23 Females

26
23

34 Males
53 Females

60

70

-

69

63 Males

63
106

114 Males
134 Females

259 Males
258 Females

80-89

lO7Males
125 Females

90+

114
13

278 Males
220 Females

79

-

259
258
107
125

— 13
— 18

13 Males

894 Males

278

220

1 8 Females
TOTAL

— = Females

53

106 Females
50-59

— = Males

34

0

10 20 30 40 50 60 70 80 90 100110120130140150160170180190200210220230240250260270280290300

937 Females

NUMBER OF PATIENTS

According to Cancer Facts & Figures-i 996, in the U.S., men have a 1 in 2 lifetime risk of developing cancer, and for women the risk is 1 in 3. However,
here at St. Luke’s Medical Center women had a slightly higher occurrence of cancer than men, with 51 % of new cancers diagnosed in 1 996 being
women and 49% being men.
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Community Education Events
June 2, 1996
“National Cancer Survivors Day”
Zablocki Park
Sponsored by The American Cancer Society
St. Luke’s Medical Center, St. Luke’s South Shore,
West Allis Memorial Hospital, WTMJ, WOKY, TV 4

February 29, 1996
“Healing and Hope: Helpful Hints for Patients and
Families Experiencing Cancer”
Kerry Twite, RN, Rev. Marcia Marino, MS, M Div
St. Luke’s New Berlin Health Care Center
March 22, 1996
“Prostate Cancer: Screening and Management”
Harold Jacobsohn, MD
St. Luke’s South Shore Auditorium

June 18, 1996

“Current Approaches to the Diagnosis and Treatment of
Breast Cancer”
Paul v. Kapelli, MD, L. Dubin, MD, Robert Taylor, MD
Paul Loewenstein, MD
Kenosha Aurora Health Care Center

April 13, 1996
“Breast Health Program”
Eastern Wisconsin Regional Cancer Center- Sheboygan

Ju1y24,1996
“Skin Cancer: The Great Cover-Up”
Pam Bauman, RT, (R)(T), BS,
Terry Pogorelc, RN, MSN, FNP
Barnes & Noble Bookstore, Greenfield

April 13, 1996
“Attitude is Everything”
1996 Breast Cancer Forum
The Italian Community Center
Sponsored by ACS & Knueppel Home Health Care

September 21, 1996
“A Symbol of Strength: Stories of Hope”
Wendy Mikkelson, MD, Mark Wenzel, MD, Kathy
Schroeder, RN, Barbara Wheeler, PhD
UWM School of Theater Arts-Music Therapy
Archbishop Cousins Catholic Center

April 23, 1996
“Learn More About Ovarian and Other Gynecological
Cancers”
Elmer Lehman, MD
St. Luke’s South Shore Auditorium

October, 1996
“Current Approaches to the Diagnosis and Treatment of
Breast Cancer”
Waukesha Aurora Health Care Center

May 5, 1996
“Strides Against Breast Cancer”
A five mile walk along the lakefront to fight breast cancer
Sponsored by St. Luke’s Medical Center in conjunction
with the American Cancer Society (ACS)

November 21,1996
“Great American Smoke Out Informational Displays”
St. Luke’s Medical Center
St. Luke’s South Shore
Vince Lombardi Cancer Clinic Slinger Site

May 5, 1996
“6th Anniversary event of the Autologous Bone Marrow
Transplant Program”
Robert Taylor, MD
St. Luke’s Medical Center

-

December 8, 1996
“Tree of Light Tree Lighting Ceremony”
St. Luke’s Medical Center

May, 1996
“Hope and Healing for Cancer Patients and Their Families”
Kerry Twite, RN
Cancer Support Group, Memorial Hospital, Burlington, WI
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Glossary
Ailogeneic: The infusion of bone marrow from one
individual (donor) to another.
Analytic Cases: Cases which are first diagnosed andlor
given their first course of treatment at St. Luke’s Medical
Center andlor St. Luke’s South Shore.
Antigen: Any substance that causes the body to produce
natural antibodies.
Autologous: The infusion of a patient’s own bone marrow
previously taken and stored.
Biopsy: The surgical removal of tissue for microscopic
examination for diagnosis.
Bone Marrow: The spongy material found inside the
bones. Most blood cells are made in the bone marrow.
Bone Marrow Transplant: The addition of bone marrow
into a patient who has been treated with high dose
chemotherapy or radiation therapy.
Bone Scan: A picture of the bones using a radioactive dye
that shows any injury, disease, or healing. A valuable test
to determine if cancer has spread to the bone, if anticancer
therapy is successful, and if affected bony areas are healing.
BRM: (Biological Response Modifier) Any agent that
boosts the body’s immune system by stimulating it,
modifying it or restoring it.
CAT Scan: A test using computers and x-rays to create
images of various parts of the body.
Clinical Trials: Studies designed to evaluate promising new
treatments by helping researchers learn which approaches
are more effective that others.
Contralateral: Relating to the opposite side.
Distant Stage: A neoplasm that has spread to other organs
or lymph nodes from the primary tumor.
Endoscope: A flexible, lighted instrument used to examine
organs such as the throat or esophagus.
Epiglottis: The flap that covers the trachea during
swallowing so that food does not enter the lungs.
First Course Treatment: The tumor-directed treatments
started within the first four months after diagnosis.
Glottis: The middle part of the larynx where the vocal
cords are located.
Immunotherapy: The artificial stimulation of the body’s
immune system to treat or fight disease.
In Situ: A tumor classified microscopically as in situ, noninvasive, pre-invasive, non-infiltrating, intraductal,
intraepithelial or intraepidermal.
Interferon: A naturally occurring body protein capable of
killing cancer cells or stopping their growth.
Interleuldn-2: (IL-2) A growth factor that stimulates cells
of the immune system to fight cancer.
Ipsilateral: On the same side.

Larynx: An organ in the throat used in breathing, swal
lowing, and talking, consisting of three parts: the
supraglottis, the glottis, and the subglottis. Also called the
voice box.
Leukoplalda: White spots or patches on the tongue or
lining of the mouth, sometimes called a precancerous
condition.
Local Stage: Tumor restricted to the organ of origin, but
may be invasive or infiltrating within the organ or origin.
Lymph Nodes: Small, bean-shaped organs located along
the lymphatic system that filter bacteria or cancer cells.
MRI (Magnetic Resonance Imaging): A sophisticated test
that provides in-depth images of organs and structures in
A
the body.
Metastasis: The spread of cancer from its original site to
distant areas. The cancer cells are carried to distant sites by
blood and lymph.
Non-Analytical: Cases which are seen at St. Luke’s
Medical Center or St. Luke’s South Shore after the first
course of treatment.
Oncology Clinical Nurse Specialist: A registered nurse with
a masters degree who specializes in the education and
reatment of cancer patients.
Oral Surgeon: A dentist with special training in surgery of
the mouth and jaw.
Otolaryngologist: (Ear, Nose & Throat) A doctor who
specializes in medical and surgical treatment of diseases of
the head and neck.
Palate: The roof of the mouth.
Pharynx: The upper part of the throat just behind the
mouth.
Regional Stage: A tumor that has extended beyond the
limits of organ of origin into 1 ) surrounding organs or
tissues by direct extension, 2) regional lymph nodes by
metastasis, or 3 ) a combination of 1 and 2 and appears to
have spread no further.
Recurrence: The return of cancer after a disease-free
interval.
Salivary Glands: Glands in the mouth that secrete saliva.
Speech Pathologist/Therapist: A specialist who evaluates
and treats people with communication and swallowing
problems.
Stage: A term used to describe the size and extent of
spread of the cancer.
Stoma: An opening made into the windpipe also called a
tracheostomy. Patients who have their larynx removed
must breathe through this opening.
Subgloms: The lowest part of the larynx; the area from
just below the vocal cords down to the top of the trachea.
Supraglottis: The upper part of the larynx, including the
epiglottis; the area above the vocal cords.
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